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Abstract 
RACHEL GRAFF: Effects of an acute bout of resistance training on leukocyte and leukocyte 
subset response in breast cancer survivors 
(Under the direction of Dr. Claudio Battaglini) 
 
 The purpose of this study was to examine the immune response to a single bout of 
moderate-intensity resistance training in breast cancer survivors (BCS). BCS (n=4) and healthy 
controls (n=8) completed an exercise session consisting of 3 sets of 10 repetitions at 70% of one 
repetition-maximum on leg press, lateral pull down, leg extension, and seated row performed in a 
circuit fashion. Blood samples taken at baseline, immediately post (0h post), 2-hours post (2h 
post), and 24-hours post (24h post) exercise were assessed for total leukocyte, granulocyte, 
lymphocyte, and monocyte cell counts. Percent change (%Δ) scores from baseline-0h post, 
baseline-2h post, and baseline-24h post were compared using mixed-model ANOVAs between 
groups and indicated that there were no significant differences between total leukocytes 
(p=0.560), granulocytes (p=0.239), lymphocytes (p=0.257), or monocytes (p=0.721) at any 
point. Results suggest BCS and controls exhibit similar immune responses to an acute bout of 
resistance training. 
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Chapter I 
Introduction 
In the year 2012, more than 200,000 people in the United States alone are expected to 
be diagnosed with invasive breast cancer (American Cancer Society, 2012). Of these, 90% 
are likely to survive for at least five years after diagnosis (ACS, 2012). Many of these 
individuals will have to undergo surgery, radiation, chemotherapy, hormonal therapies, or 
some combination of one or more of these treatments in order to survive the disease (ACS, 
2012). Cancer and its treatments have profound impacts on the physiology of its patients, 
drastically altering physical, psychological, and functional capacity and quality of life 
(Battaglini et al., 2006). Therefore, attempts to improve or reverse these negative 
physiological alterations that result from cancer and its treatments are paramount. 
Among many side-effects commonly experienced by cancer patients, severe fatigue, 
reduction in cardiopulmonary function, negative alterations in body composition, reduction 
in strength and physical functionality, along with psychosocial complications including 
depression, anxiety, and a decline in self-esteem all have been shown to significantly reduce 
the overall functionality of patients significantly compromising their overall quality of life 
(Al-Majid & Waters, 2008; Courneya, 2003; Fairey et al., 2002; Loescher et al., 1989). This 
constellation of side effects often leads to a reduction in daily physical activity levels. 
Reduced daily activity may serve to exacerbate the effects of treatments that have adverse 
effects on many different physiological systems, including the musculoskeletal and 
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cardiovascular systems (Battaglini et al., 2006; Loescher et al., 1989; Schneider et al., 2007). 
Loss of skeletal muscle, in particular, is a very frequent and undesirable effect of cancer and 
its treatments, which can negatively impact various aspects of life in cancer survivors (Al-
Majid & Waters, 2008; Courneya, 2003; Schneider et al., 2007).  
In the last couple of decades, alternative interventions, often referred to 
complementary alternative medicine (CAM) have been explored in oncology patients in an 
attempt to attenuate the severe side-effects commonly experienced by cancer patients during 
and post-completion of cancer treatments. One intervention that has gained a lot of attention 
the past few years is exercise training due its efficacious ability to positively impact many 
physiological systems that are altered during cancer treatment, its non-invasive nature, and 
relatively affordable price. Since the mid 1980s, studies have been conducted examining the 
effects of exercise on different physiological systems as well as in different cancer 
populations, with most of the studies being conducted in breast cancer patients. Most of these 
initial studies focused on aerobic forms of exercise (Courneya et al, 2003; Courneya et al. 
2006; Decker et al. 1989; Dimeo et al., 1997; MacVicar et al., 1986). It wasn’t until 2002 that 
other modes of exercise training began to be explored. Kolden et al. (2002) was the first 
research team to examine the effects of a combined aerobic and resistance exercise training 
intervention on multiple physiological parameters. In 2004, Drake and colleagues were one 
of the first groups to examine the effects of resistance training alone in cancer patients. This 
intervention was called for due to the negative effects of cancer treatments on body 
composition, an example of which is the progressive loss of muscle mass (Al-Majid & 
Waters, 2008; Cheema, et al., 2008; Schneider et al., 2007). These negative alterations in 
muscle mass are believed to be directly influenced by the effects of cancer treatments on 
3 
 
muscle cells and metabolism, often leading to reductions in protein synthesis. Resistance 
exercise, however, has shown to attenuate and even reverse the loss of muscle mass that is 
associated with cancer and its treatments (Courneya et al., 2007; Drake et al., 2004; Schmitz 
et al. 2005; Schwartz, 2007, 2009; Segal et al., 2009). 
The body of research regarding the specific role of progressive resistance training in 
cancer patients and survivors is relatively small. However, studies are demonstrating that 
resistance training holds promise in improving physical, psychosocial, and functional aspects 
in cancer patients (Cheema et al., 2007; Courneya et al., 2008; Schmitz et al., 2005; Segal et 
al., 2009). Even though these first generation studies provide important information on 
patient acceptability and tolerability for exercise training, safety and precise information on 
optimum exercise training regimens for cancer patients have yet to be determined. 
A well functioning immune system plays an integral role in maintaining overall 
health and optimal physiological function. However, cancer and its treatments are associated 
with immunodeficiency, which often lasts well beyond the completion of treatments (Fairey 
et al., 2005; Hutnick et al., 2005). The adaptive immune system is particularly influenced by 
the disease, and is often slow to recover (Hutnick et al., 2005). Therefore, cancer survivors 
often experience an increased risk of secondary infection as well as a risk of cancer 
recurrence as a result of their immunosuppressed condition (Hutnick et al., 2005). Some 
research has shown that exercise may boost immune function in cancer patients, improving 
overall health and potentially enhancing longevity (Fairey et al., 2002; Fairey et al., 2005; 
Hutnick et al., 2005). 
To date, few studies have examined the effects of exercise on the immune system in 
breast cancer patients (Fairey et al. 2005; Nieman et al., 1995; Peters et al., 1994). 
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Furthermore, most of these studies have looked at aerobic exercise modes and have only 
examined the chronic effects of exercise. Even though these studies have shown promising 
results, which demonstrate the potential that exercise training may have on improving the 
immune system of breast cancer survivors, nothing is currently known about the effects of 
one bout of exercise on the immune response of these patients. Examining markers of 
immunity such as total leukocyte and leukocyte subset counts may serve as an important 
initial step for the development of the body of knowledge regarding the response of the 
immune system to an acute bout of exercise, since these markers are routinely part of 
hematological profile analyses in cancer patients. 
In order to maximize the benefits of exercise for cancer patients, understanding their 
immune response to different intensities and modes of exercise is a paramount initial step for 
the development of future exercise prescription guidelines for optimum exercise training 
regimens. Since the use of resistance training has grown in popularity among the scientific 
community due to its potential to alleviate many of the negative side-effects associated with 
body composition and overall functionality in cancer patients, examining the effects of an 
acute bout on the immune response would allow for the development of more precise future 
interventions aimed not only at maximizing training response, but also at improving the 
safety of patients engaging in this mode of exercise training. 
Statement of Purpose 
 
 The purpose of this study was to compare the effects of an acute bout of moderate 
intensity resistance training on changes in leukocyte and leukocyte subset response between 
breast cancer survivors and apparently healthy controls, which were matched by age and 
physical activity level. Exploratory analyses examined the cortisol response to an acute bout 
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of moderate intensity resistance training, as well as the relationship between the cortisol and 
leukocyte and leukocyte subset response in both the breast cancer survivors and control 
groups.  
Hypotheses (H) 
 
H1. There will be a significantly greater difference in leukocyte, granulocyte, lymphocyte, 
and monocyte percent cell count changes from baseline to immediate post-exercise in the 
control group compared to the breast cancer survivor group.  
 
H2. There will be a significantly greater difference in leukocyte, granulocyte, lymphocyte, 
and monocyte percent cell count changes from baseline to 2 hours post-exercise in the breast 
cancer survivor group compared to the control group.  
 
H3. There will be a significantly greater difference in leukocyte, granulocyte, lymphocyte, 
and monocyte percent cell count changes from baseline to 24 hours post-exercise in the 
breast cancer survivor group compared to the control group. 
Definition of Terms 
 
Leukocytes: White blood cells that help protect the body via involvement in immune and 
inflammatory responses (Marieb & Hoehn, 2010). 
Leukocytosis: An increase in the number of leukocytes (Marieb & Hoehn, 2010). 
Lymphocytes: Agranular leukocytes that form within the bone marrow and become 
functionally mature in the lymphoid organs (Marieb & Hoehn, 2010). 
Lymphocytopenia: A reduction in the number of lymphocytes. 
Lymphocytosis: An increase in the number of lymphocytes. 
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Granulocytes: a subset of leukocytes that includes neutrophils, basophils, and eosinophils 
(Marieb & Hoehn, 2010). 
Granulocytosis: An increase in the number of granulocytes. 
Neutrophil: Most abundant type of leukocyte (makes up about 60% of total leukocytes). A 
phagocytic cell that often serves as the body’s first line of defense again infection (Marieb & 
Hoehn, 2010; Walsh et al., 2011). 
Neutrophilia: An increase in the number of neutrophils. 
Monocyte: Large leukocyte that makes up 3-8% of total leukocytes (Marieb & Hoehn, 2010). 
Monocytosis: An increase in the number of monocytes. 
Breast Cancer Survivors: Individuals diagnosed with stage I, II, or III breast cancer who have 
completed their major treatment(s), including chemotherapy, radiation, and/or surgery within 
the last 6 months and who may or may not be currently receiving hormonal therapy. 
Progressive Resistance Training: A training program where muscles work against gradually 
increasing resistance; involving implementation of the overload principle (Powers & 
Howley, 2009). 
1 Repetition Maximum (1-RM): The heaviest load that an individual can lift through a full 
range of motion one time (Tan, 1999). 
Assumptions 
 
• All participants in both groups adhered to the pre-assessment guidelines prior to 
experimental sessions. 
• All participants were honest in their responses to the medical history form 
• The amount of time since treatment completion (1 month vs. 6 months, vs. 12 
months) did not influence the patients’ immune and hormonal responses. 
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• Subjects did not change their diet between the familiarization (1-RM testing) and 
acute bout. 
Limitations 
 
• Subjects may not have complied with the dietary and exercise guidelines. To 
encourage participant compliance, subjects were asked upon arrival to verify that they 
have not eaten within the last 2 hours nor exercised within the last 12 hours. 
• The training status of the subjects prior to their enrollment in the Get REAL & HEEL 
breast cancer program was not controlled for. Therefore, training status may 
confound or interact with the results of the resistance training exercise bout. 
• The various anti-cancer treatments underwent by the subjects were not accounted for 
during analysis. 
• Diurnal rhythms of cortisol were not accounted for.  
Delimitations 
 
• All subjects in the breast cancer survivor group had completed chemotherapy and/or 
radiation treatments within 12 months of the experimental sessions. 
• Subjects in the breast cancer survivor group were not taking any medications that 
may influence the response of the immune system, other than hormonal therapy (i.e., 
Tamoxifen). 
• All subjects in the control group were healthy with no contraindications to 
participating in resistance exercise, and not taking any medications that may influence 
the response of the immune system. 
• All subjects in both groups did not have any range of motion restrictions that 
impaired their ability to participate in the resistance exercise session. 
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Significance 
 
It is necessary for exercise science professionals to account for the effects of exercise 
training sessions on immune function when designing training regimens for their clients. This 
includes being aware of the extent to which the immune system is suppressed following 
certain types of training, and making certain to allocate adequate recovery time before 
implementing another training session. In athletes, the continuous implementation of 
consecutive training bouts with inadequate recovery time is suggested to facilitate 
immunosuppression and the onset of the Overtraining Syndrome (Gleeson, 2002). While 
breast cancer survivors are not likely to be performing exercise at the same level or intensity 
as high-level athletes, it remains important that the implementation of exercise training in this 
population does not result in further chronic immunosuppression in addition to that caused by 
the various anti-cancer treatments. 
To ensure that the suppression of the immune systems of breast cancer survivors is 
not being exacerbated by exercise training programs, it is essential for the timeline of 
immune recovery following a single exercise session be known. A secondary training session 
should not be implemented until the potential immunosuppressive effects of the primary 
training session recover fully, so as to avoid prolonged impairment of the immune system 
(Gleeson, 2001; Koch, 2010).  As the immune system responds somewhat differently to the 
various types of training (i.e. endurance versus resistance training), it is necessary that the 
timeline of recovery be known for both in order to facilitate a more precise program design 
that will enhance the immune function of this population as opposed to inhibiting it (Koch, 
2010). 
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Chapter II 
Review of the Literature 
Introduction 
 This review of the literature is divided into 6 sections. Section 1 will discuss breast 
cancer and its treatments; section 2 will review physical activity in breast cancer patients; 
section 3 will discuss the current research on resistance exercise in cancer patients; section 4 
will introduce the relationship between cancer and the immune system; section 5 will focus 
on the relationship between acute exercise and the immune response; and section 6 will 
summarize the potential implications of exercise, particularly resistance exercise, in breast 
cancer survivors. 
Breast Cancer Prevalence and Treatments 
 
 The prevalence of breast cancer within the United States has continually increased 
over the last number of years. Today, 1 out of 8 women will be diagnosed with breast cancer 
at some point in her lifetime (American Cancer Society, 2012). Surgery, radiation, 
chemotherapy, and hormonal therapies comprise the list of the various treatments that these 
individuals may have to endure, and they are each accompanied by a vast array of side 
effects, which can drastically influence physiological factors and quality of life (ACS, 2012; 
Courneya, 2003).  
Surgery may be accompanied by infection, decreased function, reduced range of 
motion (ROM), diarrhea, shortness of breath, pain, numbness, and lymphedema (Courneya, 
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2003). Radiation treatment is associated with potential toxicity to irradiated normal tissue, 
pain and blistering, reductions in ROM, fatigue, diarrhea, lung fibrosis, and damage to 
cardiac myocytes (Courneya, 2003). Chemotherapy is often coupled with side effects such as 
fatigue, reduced appetite, nausea, anemia, reduction in neutrophil counts, peripheral 
neuropathy, ataxia, and cardiotoxicity (Courneya, 2003). Finally, hormonal therapy typically 
results in weight gain, sarcopenia, muscle weakness, increases in adiposity (particularly 
within the torso and face), bone loss, fatigue, hot flashes, and immunosuppression 
(Courneya, 2003). Following a breast cancer diagnosis, individuals will often undergo one or 
more of these treatments, which clearly exhibit monumental influences upon various aspects 
of human physiology. 
Physical Activity and Breast Cancer 
 
Until recently, participation in regular physical activity for individuals undergoing 
and recovering from cancer treatments was contraindicated by medical professionals 
(Battaglini et al., 2006). Within the last several years, however, there has been a growing 
body of evidence to suggest that participation in a regular exercise program can be extremely 
beneficial in mediating and even reversing many of the aforementioned side effects 
associated with cancer treatments both during and following cancer treatments. Although the 
first study to incorporate resistance training in cancer patients was conducted in 2002, 
successive studies over the past 10 years have demonstrated that resistance training shows 
promise in enabling the improvement in a wider range of treatment-related side effects than 
cardiovascular training alone (Kolden et al., 2002). 
Skeletal muscle loss is a common problem in cancer patients both during and after the 
completion of various cancer treatments (Al-Majid &Waters, 2008; Schneider et al., 2007). 
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In addition to metabolic effects, the time period following a cancer diagnosis is often coupled 
with an increase in inactivity, which contributes to further muscle loss (Al-Majid & Waters, 
2008; Schneider et al., 2007). Metabolically, individuals diagnosed with cancer typically 
experience a decrease in protein synthesis and a subsequent increase in protein degradation 
(Al-Majid & Waters, 2008; Schneider et al., 2007). In other words, cancer patients’ bodies 
are unable to re-build skeletal muscle at the same rate at which it is being broken down. It is 
suggested that the reduction in protein synthesis may be due to one or more of the following:  
increased levels of tumor-released proteolysis-inducing factor, angiotensin II, disruption of 
the mTOR pathway, and a reduction in daily physical activity levels as a result of fatigue and 
muscle weakness (Al-Majid & Waters, 2008). It is also possible that the reduction in physical 
activity can play a role in exacerbating the metabolic effects on the reduction in protein 
synthesis (Al-Majid & Waters, 2008). 
In addition, the increase in skeletal muscle protein degradation may be attributed to 
an activation of various proteolytic mechanisms. One such mechanism is the non-lysosomal 
calcium-dependent protease system that is responsible for the release of calpains, which 
break down the myofibrils that comprise skeletal muscle fibers. Another, is the ubiquitin-
proteasome system, which breaks down damaged proteins in healthy individuals, but shows 
increased activity within the skeletal muscles of cancer patients. A third, is an increase in the 
amounts of pro-inflammatory cytokines such as tumor necrosis factor- alpha (TNF-α), 
interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon-gamma (IFN- γ) within the bodies of 
individuals with cancer, which are suggested to indirectly activate the ubiquitin-proteasome 
system (Al-Majid & Waters, 2008; Schneider et al., 2007). The combination of these factors, 
which contribute to the reduction in protein synthesis and an increase in protein degradation 
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within the skeletal muscles of individuals with cancer serve to comprise the cachexia, or 
skeletal muscle wasting, experienced by cancer patients. 
Resistance Exercise in Cancer Patients 
 
Progressive resistance training in healthy individuals is responsible for providing a 
stimulus to increase the amount of skeletal muscle protein synthesis. This may be due, in 
part, to the anti-inflammatory effect of resistance training. Resistance training has 
demonstrated a reduction in pro-inflammatory cytokine levels, which as previously 
mentioned, are suggested to indirectly activate the ubiquitin-proteasome system, contributing 
to skeletal muscle breakdown (Al-Majid & Waters, 2008). By reducing the release of pro-
inflammatory cytokines and thereby the indirect stimulation of the ubiquitin-proteasome 
system, protein degradation may be prevented. Further, resistance training has been shown to 
affect the mTOR pathway, which as previously mentioned, is another mechanism of protein 
synthesis that is oftentimes disrupted as a result of cancer and its treatments. In healthy 
individuals, resistance training significantly stimulates the mTOR pathway within skeletal 
muscle cells, thereby promoting skeletal muscle protein synthesis (Al-Majid & Waters, 2008; 
Spiering et al., 2008). Therefore, resistance exercise may be beneficial in cancer patients by 
opposing several cancer-related mechanisms that contribute to skeletal muscle loss. 
To date, the majority of the research studies involving exercise and cancer patients 
have been done on individuals with breast cancer (Galvao & Newton, 2005). Further, most of 
the exercise interventions have prescribed either aerobic only, or combined aerobic and 
resistance training interventions, with very few examining the effects of resistance training 
alone (Cheema et al., 2008). Overall, however, progressive resistance training in cancer 
patients is continuously proving to be safe and beneficial in individuals recovering from 
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cancer and its treatments, as it can improve various aspects of physiology and quality of life 
without the occurrence of any serious adverse effects (Cheema, et al., 2008; Drake et al., 
2004; Galvao et al., 2006; Galvao et al., 2008; Schwartz et al, 2007; Schwartz & Winters-
Stone 2009).  
In a study by Segal et al., (2009), men currently receiving radiation treatment for 
prostate cancer were divided into resistance exercise, aerobic exercise, and non-exercise 
control groups. The exercise groups each trained 3 times a week for 24 weeks with 
progression as participants became more physically fit.  Results indicated that the resistance 
exercise group resulted in greater improvements in cancer-specific quality of life, muscular 
strength, triglycerides, and body composition than the aerobic training group. Both resistance 
and aerobic training groups had a positive effect on reducing levels of fatigue and in 
improving aerobic fitness. Even though this study was conducted in men with prostate cancer 
who were undergoing radiation treatment, it suggests that resistance exercise could 
potentially play an important role in individuals with other types of cancer who have 
undergone radiation therapy. 
A different study by Schneider et al. (2007) examined the effects of combined aerobic 
and resistance training on breast and prostate cancer patients. Participants exercised 2-3 times 
per week over the course of 6 months.  At the end of the training period, the group that had 
completed treatment prior to the exercise intervention demonstrated increased muscular 
endurance, significantly reduced depression, and increased quality of life. Along the same 
lines, De Backer et al., (2007) exercised 57 cancer survivors using high intensity resistance 
training and aerobic interval training over the course of 18 weeks. After the training period, 
results showed significant increases in muscular strength, maximal oxygen consumption 
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(VO2max), and health-related quality of life. In sum, these studies indicated that moderate to 
high intensity combined resistance and aerobic exercise training in cancer patients and 
survivors can improve muscular strength, performance, and quality of life as well as the 
functionality of cancer survivors. 
Schmitz et al. (2005) and Courneya et al. (2007) both employed the use of resistance 
training in isolation in breast cancer survivors and breast cancer patients undergoing 
chemotherapy, respectively. Both studies found significant improvements in body 
composition and muscular strength, and were well tolerated by the participants. Schmitz et al. 
(2005) noted significant reductions in body fat percentages over the 6-12 month training 
period, which has important implications in preventing cancer recurrence. Courneya et al., 
(2007) reported that in addition to the improvements in body composition and muscular 
strength, resistance training was in fact superior to aerobic training in increasing self esteem 
and chemotherapy completion rate in participants over the course of the training intervention. 
Although research on resistance training alone in breast cancer patients and survivors is 
limited, it appears to have positive influences on many of the ailments caused by a cancer 
diagnosis and its subsequent treatments. 
Relationship Between Cancer and the Immune System 
 
 Cancer and its treatments are linked to deviations in immune function from that of 
healthy individuals. During and following treatment, cancer patients typically experience 
immunosuppression and hence, an increase in their susceptibility to secondary infection as 
well as cancer recurrence (Courneya, 2003; Fairey et al., 2005; Hutnick et al., 2005). This 
immunosuppression can be observed in both the innate and the adaptive immune cells 
(Fairey et al., 2005; Hutnick et al., 2005).  
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 The innate immune system is typically the body’s first line of defense against 
invading pathogens. The cellular components of the innate response include neutrophils (a 
subset of granulocytes, which comprise about 60% of all circulating leukocytes), 
macrophages (which come from the maturation of monocytes), natural killer (NK) cells (a 
subset of lymphocytes), and dendritic cells (Koch, 2010; Walsh et al., 2011). These cells 
provide non-specific protection of the host against any foreign or non-self components that 
exist within the body (Walsh et al., 2011). 
 The cellular components of the adaptive immune system consist primarily of the 
various lymphocyte subpopulations with the exception of NK cells, which are part of the 
innate immune system. The basic lymphocyte subpopulations are divided into T-helper cells 
(CD4+), T-cytotoxic cells (CD8+), and B-cells, which can be further divided into additional 
subsets (Walsh et al., 2011). These cellular components are typically activated by the innate 
immune response to a particular antigen or abnormal body cell and undergo a cascade of 
events to enable the body to more effectively fight off the foreign invader or abnormal cell 
via antibody production or apoptosis (programmed cell death). Therefore, the duration of the 
adaptive response may take much longer than that of the innate response. Once the antigen or 
non-self component is effectively removed from the body, memory T-cells and B-cells 
remain so that upon secondary exposure, the body can respond more quickly and efficiently 
to wipe out the invader (Marieb & Hoehn, 2010). 
 In breast cancer survivors specifically, fatigue is a major problem experienced by 
many individuals for months or even years after the completion of treatment (Bower et al., 
2002; Servaes, Verhagen, & Bleijenberg, 2002). A study by Bower et al. (2002) examined 
some of the cellular immune markers in fatigued breast cancer survivors who had completed 
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all cancer treatments aside from tamoxifen and found that these individuals had lower 
proportions of NK cells and T-helper cells than those who were not fatigued. It is suggested 
that these lymphocyte subsets are particularly slow to recover following cancer treatment, 
and may be affected for up to five years after chemotherapy and radiation treatments (Bower 
et al., 2002; Hutnick et al., 2005). 
 The cellular components of the innate and adaptive immune systems have immense 
implications for cancer patients and survivors. The cells of both immune systems have 
important roles in protecting the body from tumor formation as well as infection from outside 
elements (Marieb & Hoehn, 2010; Walsh et al., 2011). Both groups of cells are affected by 
cancer and anti-cancer therapies. Cancer and its treatments have been shown to reduce both 
the number and the functionality of lymphocytes (T-cells, B-cells, and NK cells), neutrophils, 
and macrophages (Fairey et al., 2005). Even after the completion of treatment, many of these 
components are unable to recover in a timely fashion (Fairey et al., 2005; Hutnick et al., 
2005). Therefore, these individuals are more likely to develop additional infections or cancer 
recurrence. However, exercise has shown to play a mediating role in immune regulation and 
may potentially serve as a form of immunotherapy to help improve the immune systems of 
cancer survivors (Fairey et al., 2005; Hutnick et al., 2005). 
Acute Exercise and the Immune Response 
 
 It is suggested that one’s level of physical activity plays a role in overall immune 
function and susceptibility to infection. This can be depicted by a “J-shaped curve” indicating 
that moderate levels of daily physical activity result in enhanced immune function, whereas a 
sedentary lifestyle and extremely high levels of physical activity are suggested to impair 
various immune parameters (Nieman, 1997). This can be further explained by the “open 
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window” theory, which portrays the immune response to a single bout of acute exercise 
(Pederson, 1999). According to this theory, a single exercise bout can result in an initial up-
regulation in immune parameters followed by a subsequent down-regulation of these 
parameters, which can last up to 72 hours post-exercise (Pederson et al., 1999). In other 
words, following a single exercise bout, immune function may increase immediately 
following the exercise session and then may decrease below baseline, thereby increasing 
susceptibility to infection. The magnitude of this immunosuppression is directly proportional 
to the intensity and duration of the exercise performed (Pedersen et al., 1999). 
 The majority of the research to date is focused on the effects of endurance training on 
the immune system. Therefore, much less is known about the impact of resistance training 
(Koch, 2010; Walsh et al., 2011). As a result of endurance exercise, an immediate and 
significant increase in neutrophils, a subset of granulocytes, is observed. This immediate 
neutrophilia is due primarily to catecholamine release and the shear stress exerted by an 
increase in cardiac output against the blood vessel walls that occur during exercise (Walsh et 
al., 2011). Several hours following the acute exercise bout, a secondary increase in 
circulating neutrophils is typically observed. This is suggested to be mediated by cortisol, 
which stimulates neutrophil release from the bone marrow (Walsh et al., 2011).  
 A single bout of aerobic exercise has substantial influence on the levels of circulating 
lymphocytes as well. During and immediately following moderate or intense exercise, there 
is an up-regulation in lymphocyte concentrations, which can then plummet below baseline 
levels during recovery (Nieman et al., 1991; Pedersen & Hoffman Goetz, 2000). This initial 
increase in circulating lymphocytes is explained by the recruitment of all lymphocyte 
subpopulations (T-helper, T-cytotoxic, B-cells, and NK cells) into the circulation, possibly 
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from the spleen, lymph nodes, and gastrointestinal tract (Pedersen & Hoffman-Goetz, 2000). 
This recruitment is thought to be a response to increases in catecholamine levels as well as 
increases in cardiac output that typically accompany exercise sessions (Koch, 2010). 
However, cortisol, which is often released during prolonged or intense exercise is 
associated with immunosuppression (Neves Jr. et.al., 2009). It has an inhibitory effect on the 
proliferative response of lymphocytes, suggesting that cortisol impairs the ability of 
lymphocytes to respond to antigens (Nieman, 1997). The inhibitory effects of cortisol 
coupled with a redistribution of lymphocytes to respective body tissues are likely 
explanations for the decrease in circulating lymphocytes observed after acute exercise 
(Gleeson, 2007; Pedersen & Hoffman-Goetz, 2000). An intensity threshold of 40% to 60% of 
VO2max has been established as the aerobic intensity threshold for initiation of 
lymphocytopenia, or the reduction in circulating lymphocytes following the cessation of 
exercise (Koch, 2010).  
Levels of circulating monocytes are also affected by acute endurance exercise 
(Pedersen & Hoffman-Goetz, 2000). However, increase in monocyte concentration is 
typically not observed until about 2 hours post-exercise (Walsh et al., 2011). This 
monocytosis is suggested to be mediated by either plasma volume shift, exercise-induced 
cortisol release, exercise-induced catecholamine release, or some combination of the three 
(Walsh et al., 2011). While monocytes are relatively immature cells, they are responsible for 
the release of a variety of cytokines which can exacerbate systemic inflammation (Smith, 
2000). However, monocytes also serve as an integral component of innate immunity. They 
mature into macrophages, which play a major phagocytic role in ridding the body of foreign 
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substances (Marieb & Hoehn, 2010). Prolonged elevation in active macrophages can be 
indicative of chronic inflammation (Marieb & Hoehn, 2010). 
As a result of moderate intensity endurance exercise, the leukocytosis observed 
immediately post-workout is often less pronounced than following intense endurance 
exercise (Koch, 2010). Further, the lymphocytopenia, or the reduction in circulating 
lymphocytes below baseline levels, is also of a smaller magnitude following moderate-
intensity endurance exercise compared to high-intensity endurance exercise (Koch, 2010). It 
is suggested that the immune system responds similarly to resistance exercise as well, 
however, the lymphocyte response to resistance exercise has not been clearly established 
(Koch, 2010). 
It appears that the immunosuppression following an acute bout of resistance exercise 
is less pronounced than that of the response following aerobic exercise (Neves Jr. et al., 
2009). In the study by Neves Jr. et al. (2009), older women experienced an increase in 
circulating leukocytes following an acute bout of resistance training with no 
immunosuppression observed during the recovery period. In fact, this study observed 
elevated lymphocyte levels at 3 hours post-exercise. The absence of observable 
immunosuppression was suggested to be due to a lack of cortisol elevation during the 
resistance exercise protocol, as cortisol is associated with initiating many of the 
immunosuppressive effects observed following endurance-type exercise sessions. 
Because cortisol is suggested to be such a prominent mediating factor in exercise-
induced immunosuppression (particularly within the lymphocyte subpopulations) typically 
observed in the recovery period following exercise, resistance training can have profound 
implications regarding exercise program design with the intent of improving immune 
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function (Neves Jr. et al., 2009). In a study by Kraemer et al. (1996), subjects underwent two 
identical high-intensity resistance training exercise sessions, with the only difference 
between the two being the rest period between subsequent sets. One protocol required 3 
minutes of rest in between sets, whereas the other limited recovery to 1 minute between sets. 
Results indicated that while cortisol was significantly elevated within the 1 minute rest 
protocol, it was not significantly elevated within the 3 minute rest protocol even though the 
absolute work performed during both protocols was the same. The authors further observed 
that in the immediately post-exercise blood sample, both protocols initiated a similar 
leukocytosis. This is important because it suggests that the increase in circulating leukocytes 
is caused by factors unrelated to cortisol release during exercise, and that manipulating the 
rest period between subsequent sets of heavy resistance training exercises can influence 
whether or not cortisol is significantly elevated. 
It is clear that exercise has a significant influence on the levels of circulating 
leukocytes. These effects seem to vary with differing training variables, such as intensity, 
duration, and mode of exercise. Even though the research exploring the influence of 
resistance training on these immune parameters is somewhat limited, the manipulation of 
various resistance training variables may have important implications in enabling the 
maximization of immune function, especially for those clinical populations, like cancer 
patients, to whom optimal immune function is essential to enhancing quality of life and 
preventing cancer recurrence. 
Exercise and Immune Function: Implications for Breast Cancer Survivors 
 
 The majority of the research regarding immune function in cancer survivors has 
focused on the effects of training programs on immune parameters (Fairey et al., 2002). 
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These programs included either aerobic only training, or a combined aerobic and resistance 
training regimen, with little emphasis placed on resistance-training only interventions (Fairey 
et al., 2002). Overall, training studies involving cancer survivors indicate that exercise 
training can have a positive effect on immune function in these individuals (Fariey et al., 
2002). 
 In addition, there are limited established exercise program design parameters for 
cancer populations (Schmitz et al., 2010). The American College of Sports Medicine has 
published a consensus regarding exercise guidelines for cancer survivors. However, large 
gaps remain in the prescription of certain training variables, such as frequency, duration, and 
intensity, particularly when pertaining to resistance training (Schmitz et al., 2010). Hence, 
the training intervention designs between studies are rarely homogenous, and consequently 
difficult to compare. Therefore, criteria for exercise prescription to improve immune function 
in cancer survivors must be derived from the limited data available, and often from studies 
involving alternate populations. 
 A study conducted by Fairey et al. (2005) examined the effects of aerobic exercise 
performed 3 times per week on immune function in breast cancer survivors. Results showed 
that at the end of the 15 week intervention, NK cell function was significantly greater than 
non-exercise control group. The results are important because optimal NK cell function is 
associated with disease free, overall survival rates, while poor NK function is indicative of an 
increased risk of cancer recurrence (Fairey et al., 2005). Even though this was an aerobic 
intervention and a training study, it is important because it demonstrates the role exercise can 
play in improving immune function in this population. 
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 Taking this one step further, Hutnick et al. (2005) examined the effects of a mixed 
aerobic and resistance training intervention on lymphocyte function in breast cancer 
survivors. Before the initiation of the training program, all of the participants had mean 
lymphocyte subset values below the interquartile range for healthy individuals. After the 3 to 
6 month training period, results indicated that circulating levels of T-helper cells had 
increased proliferative capacity following the training period in the exercise group, but not in 
the non-exercising control group. The authors suggest that exercise training may emerge as a 
sort of immunotherapy for breast cancer survivors, aiding them in the prevention of 
secondary infections as well as cancer recurrence. 
 Ramel et al. (2003) examined the immune response to an acute bout of resistance 
exercise in healthy men. Subjects performed a resistance exercise circuit consisting of 10 
exercises focusing on the major muscle groups at 75% of 1 RM with 1 minute of rest in 
between each exercise and completed the 10-exercise circuit 2-3 times each. Results 
indicated that total leukocytes and leukocyte subset (NK cells, neutrophils, total 
lymphocytes, and monocytes) values were increased during and immediately following the 
exercise bout. While neutrophils and monocytes remained significantly elevated throughout 
the 120 minute recovery period, lymphocyte values dropped below baseline after the 
cessation of exercise, returning to above baseline values at 120 minutes into recovery. The 
changes in lymphocyte concentrations were negatively associated with cortisol levels, 
indicating that cortisol played a mediating role in this process of altered immune function. 
However, the authors stressed that the hormonal response of noradrenaline and cortisol to 
resistance exercise is moderate when compared with endurance exercise.  
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These conclusions suggest that resistance exercise may play less of an inhibitory role 
in immune function in healthy males, particularly that of lymphocytes whose fluctuations 
appear to be directly related to the magnitude of cortisol release. As lymphocyte levels and 
function appear to be sub-optimal in breast cancer survivors following cancer treatments, the 
implementation of resistance exercise may be beneficial in improving lymphocyte function in 
these individuals. 
Summary and Significance 
 
The current research in exercise science points to positive effects on the immune 
system as just one of the many benefits to be obtained from exercise. Knowledge regarding 
the influence of exercise on the immune system is integral to creating optimal program 
design for specific populations. For example, athletes, who typically employ the use of 
prolonged, high intensity training bouts must allow adequate time for their immune systems 
to recover before implementing a second intense training bout. Failure to allot adequate time 
for the recovery of the immune system may result in further immunosuppression with 
additional training and may eventually culminate in the overtraining syndrome, in which the 
athlete’s performance will regress to sub-optimal levels despite additional athletic training 
(Gleeson, 2002). Likewise, it is necessary for exercise professionals to be aware of the 
timeline in which breast cancer survivors’ immune systems recover from acute bouts of 
exercise when coming up with an exercise prescription for this population. This knowledge 
would allow for the establishment of guidelines regarding recovery periods between 
consecutive exercise sessions that would not inhibit, and would perhaps enhance the immune 
functions of these individuals over time. It would provide vital information concerning 
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precautions that should be taken against training these individuals to the point where their 
immune function may be further depressed by subsequent training bouts. 
Breast cancer survivors, who are already immunosuppressed following anti-cancer 
treatments, comprise a population that can benefit immensely from regular participation in 
resistance exercise training. In addition to the variety of benefits initiated by resistance 
training on physiological variables including increased functional capacity, increased muscle 
mass, improved body composition, increased quality of life, reductions in muscle wasting 
and sarcopenia, and decreased risk of osteoporosis, resistance training is also showing 
promise as a means of potentially enhancing various aspects of the immune system. As such, 
implementing regular resistance exercise in the breast cancer survivor population may reduce 
the risk of secondary infection, reduce the risk of cancer recurrence, and ultimately improve 
length and quality of life. 
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Chapter III 
Methodology 
Subjects 
 Participants of this study consisted of 4 female early stage breast cancer (stage I-III) 
survivors and 8 healthy controls. The breast cancer survivor inclusion criteria consisted of: 
being a female between 40 and 72 years old, being within 4-12 months post breast cancer 
treatment (having undergone chemotherapy treatment at minimum), not taking any anti-
inflammatory medications, and having clearance from their oncologists to participate in the 
present study. Patients receiving adjuvant hormonal therapy or adjuvant trastuzumab were 
also eligible to participate in the study.  
Inclusion criteria for the control group consisted of: apparently healthy, 40 to 70 year 
old females, no history of cancer diagnosis or treatment, no limitations in range of motion 
that would impede upon the ability to perform the prescribed resistance training exercises 
safely, not taking any anti-inflammatory medications, and clearance from their primary 
physician to participate in the study for subjects older than 65 years of age. All control 
subjects were matched by age (within 5 years) with the breast cancer group. Also, all 
attempts were made to match control subjects with the breast cancer group based on physical 
activity level.  
Exclusion criteria for all subjects was determined by a screening based on the ACSM 
guidelines set forth to determine contraindications to exercise participation (Whaley, 
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Brubaker, & Otto, 2006). Information regarding the exclusion criteria was obtained from 
each subject based on their responses to their medical history and from a medical and 
physical screening. 
Recruitment 
 
 Participants for the breast cancer survivor group were recruited from UNC Hospital’s 
Breast Cancer Care Clinic and from the Get REAL & HEEL Breast Cancer Program at the 
University of North Carolina, Chapel Hill. Participants for the control group were recruited 
by the posting of flyers at various locations throughout the campus of the University of North 
Carolina, Chapel Hill, via informational emails sent out to the campus community at the 
University of North Carolina, Chapel Hill, as well as through word of mouth. 
Instrumentation 
 
Anthropometric Measures: Resting cardiac function was assessed using a GE CASE 
Cardiosoft V. 6.6 ECG diagnostic system (Palatine, IL). Height was taken using a 
Perspective Enterprises Stadiometer (Portage, MI). Weight was obtained via a Detecto Scale 
(Webb City, MO). A Discovery Dual Energy X-Ray Absorption (DEXA) scanner (Bedford, 
MA) was used to assess body composition.  
 Exercise Testing: Blood pressure was assessed before and after the exercise protocol 
using a sphygmomanometer (American Diagnostics Corporation, Hauppage, NY) and a 
Littmann® Stethoscope (St. Paul, MN).  Heart rate before and throughout the exercise 
protocol was assessed using a Polar telemetry system (Lake Success, NY). The warm-up 
period was performed on a Lode electronically-braked cycle ergometer (Gronigen, The 
Netherlands). The exercise components were performed on a seated leg press (Cybex, 
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Medway, MA), lateral pull down machine (Cybex, Medway, MA), seated leg extension (Life 
Fitness, Schiller Park, IL), and a seated row (Life Fitness, Schiller Park, IL). 
 Blood Analyses: Blood was taken at 4 time intervals throughout the study. The first 
three were done using a 22 gage Protectiv Plus catheter (Ethicon Endo-Surgery Inc., 
Cincinnati, OH). The fourth was done using standard venipuncture techniques. Blood was 
collected in 10.8 mg K3EDTA BD Vacutainers ® (Franklin Lakes, NJ). Total leukocyte, 
granulocyte, lymphocyte, and monocyte counts were determined using a Coulter AC T diff 
Hematology Analyzer (Block Scientific, Inc., Bohemia, NY). Blood cortisol values were 
determined using a cortisol ELISA Kit, KA 0981, Abnova Version 2, (Tapei City, Taiwan). 
General Procedures 
 
The general timeline for the experimental protocol is depicted in Figure 1. 
 Familiarization Session: Medical history forms and pre-assessment guidelines were 
administered to subjects via email correspondence prior to their first visit to the lab for 
experimental testing. Once they arrived, these forms were reviewed to confirm that all 
subjects met the inclusion criteria for the present study. Subjects then signed an informed 
consent form detailing the experimental protocol and potential risks and benefits associated 
with participation in the study. Next, subjects underwent a medical and physical screening to 
determine if there were any contraindications to exercise by a member of the research team 
who is certified/authorized by the UNC school of medicine to perform physicals for exercise 
testing. After receiving clearance to participate in the study, adherence to pre-assessment 
guidelines was reviewed. Pre-assessment guidelines consisted of: no eating for at least 2 hours 
prior to the lab visit; no exercise for at least 12 hours prior to the lab visit; drink water 
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throughout the day to stay hydrated; No caffeine use for at last 12 hours prior to the lab visit; 
No alcohol use for at least 48 hours prior to the lab visit.  
Height and weight were then taken, and subjects underwent a body composition 
assessment using the DEXA. Following this, they were fitted with a heart rate monitor and 
rested in the seated position for 10 minutes, at which time resting heart rate and blood 
pressure were recorded. Subjects then underwent a 5-10 minute warm-up consisting of 
unloaded cycling on a cycle ergometer, while keeping their heart rates around 40 - 50% of 
heart rate reserve (HRR), as calculated by the Karvonen formula.  
After the warm-up, subjects were familiarized with the resistance training equipment 
that was used in the experimental protocol by undergoing approximately 10 repetitions of 
each exercise using minimal resistance. Following initial exposure to each of the resistance 
exercise machines in the same order in which they were used during the experimental 
protocol, each subject’s 1 RM values were obtained on the leg press, lateral pull down 
(LPD), leg extension, and seated row exercises using the protocol as described by Levinger et 
al. (2009). The order of exercises during the experimental protocol was as follows: leg press, 
lateral pull down, leg extension, and seated row. Therefore, 1 RM values were taken in that 
order as well to account for any neuromuscular fatigue obtained from the preceding exercise. 
Heart rate was monitored continuously throughout the exercise session. 
Upon the completion of the familiarization trial, subjects were asked to rest for 10 
minutes, after which heart rate and blood pressure were taken again. If these measures were 
abnormally elevated, subjects were asked to remain seated until the values decreased. If 
within normal values, subjects were released and asked to return to the lab for their second 
lab visit appointment. 
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Experimental Session: The second lab visit took place between 1.5 and 14 days 
following the familiarization session. Upon arrival, subjects put on a heart rate monitor and 
rested in the seated position, during which time adherence to the pre-assessment guidelines 
was reviewed. A Psychological Stress Scale (PSS) was also administered to determine if the 
subject was experiencing psychological stress, which could affect the release of the stress 
hormones which were measured during the study. A resting heart rate and blood pressure 
were taken. Again, if either of these values were not within normal range for the individual, 
the subject was asked to return to the lab on a different day. 
 The subjects then underwent catheter placement into an antecubital vein in the arm 
for blood sampling by a faculty member in the Department of Exercise and Sport Science 
who has been trained and certified in phlebotomy techniques. After this, subjects rested in the 
seated position for approximately 10 minutes, and then the first pre-exercise blood sample 
was collected. A 5 minute warm-up consisting of unloaded cycling on a cycle ergometer 
followed, again keeping subjects’ heart rates around 40 - 50% of HRR. Subjects then 
performed several repetitions of each of the four resistance exercises with minimal weight to 
ensure that their muscles were adequately prepared for the resistance protocol. After the 
warm up, the resistance training protocol began. Subjects performed 10 repetitions at 70% of 
1-RM of each exercise (leg press, lateral pull down, leg extension, and seated row, 
respectively) with 30 to 45 seconds of rest between subsequent exercises, and 1 minute and 
30 seconds to 2 minutes of rest between subsequent circuits. This circuit was completed three 
times. Heart rate and RPE were taken following each set to ensure subject safety and monitor 
their conditions. Subjects were encouraged to consume water at any point during and 
following the experimental protocol. 
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Directly upon completion of the third circuit of exercises, subjects were seated and a 
blood sample was taken immediately post-exercise. Subjects were then sequestered for the 
next 2 hours, during which time they were encouraged to consume plenty of water and to 
relax. They were allowed to perform a brief series of light stretches. Following this 2 hour 
period, the 2 hour post-exercise blood sample was taken, after which the subjects were 
encouraged to eat a snack of their choice. The catheter was removed, any necessary 
bandaging was performed, and the subjects was reminded not to perform any kind of 
strenuous activity over the next 24 hours, and to adhere, once again, to the pre-assessment 
guidelines before their third and final lab visit. 
24 Hour Blood Draw: Twenty-four hours following the completion of the resistance 
exercise session, subjects returned to the lab for their 24 hour post-exercise blood draw. 
There was a 1-hour window at which this blood sample will be taken. In other words, 
subjects may come in for their third visit 30 minutes prior to the time of exercise completion 
session on the previous day, or 30 minutes after the time of completion of the exercise 
session on the previous day. Adherence to the pre-assessment guidelines was reviewed, and 
the blood sample was taken by a certified phlebotomist using a 22 gage needle. After 
obtaining the blood sample, subjects have completed the experimental procedure. The blood-
draw timeline is depicted in Figure 2.  
All data was adjusted to account for plasma volume shift (the shift of fluid out of the 
vascular system that occurs as a result of exercise) prior to statistical analysis using the Dill 
and Costill method (Dill & Costill, 1974). Plasma volume shifts are reported in order to 
account for the influence of exercise on fluid shift, which may in turn influence the 
concentrations of leukocytes, leukocyte subsets, and cortisol.  
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Statistical Analysis: 
Descriptive statistics are presented in the form of means and standard deviations. The 
independent variables for this analysis include subject condition (breast cancer survivor and 
healthy control) and the acute bout of resistance training. The dependent variables are the 
total leukocyte, granulocyte, lymphocyte, and monocyte counts at the various time intervals 
(immediately pre-exercise, immediately post-exercise, 2 hours post-exercise, and 24 hours 
post-exercise). All data was analyzed using SPSS version 20.0 (Chicago, IL). Statistical 
significance was set a priori at an alpha-level of p ≤ 0.05. 
Hypotheses 1, 2, and 3 were analyzed using 2 x 3 mixed model ANOVAs. The 
between subjects factor is subject condition (breast cancer survivor or healthy control). The 
within subjects factor is the percent change of cell counts (% change = immediately post-
exercise count – pre-exercise count/ pre-exercise count x 100; % change = 2 hours post-
exercise count – pre-exercise count / pre-exercise count x 100; and % change = 24 hours 
post-exercise count – pre-exercise count / pre-exercise count x 100, respectively) for each 
dependent variable (leukocytes, granulocytes, lymphocytes, and monocytes cell count).   
 Exploratory analyses were conducted to evaluate the cortisol response in both the 
breast cancer survivor group and the control group to the acute bout of moderate-intensity 
resistance training by using a Mann Whitney U analysis to test for between group (breast 
cancer survivor compared to healthy control) differences in cortisol response, and a Friedman 
test for each of the conditions (breast cancer survivor or healthy control) to examine within 
group differences at baseline, immediately post-exercise, 2 hours post exercise and 24 hours 
post exercise. 
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Chapter IV 
Results 
The primary purpose of this study was to compare the effects of an acute bout of 
resistance training on percent cell count changes in leukocyte and leukocyte subset values in 
breast cancer survivors and healthy controls. A secondary purpose was to conduct 
exploratory analyses on cortisol to examine the cortisol response to an acute bout of 
moderate intensity resistance training in both the breast cancer survivors and control groups, 
since cortisol has been shown to be a potential mediator of some cellular immune responses. 
Participants consisted of 4 breast cancer survivors and 8 healthy controls. Descriptive 
characteristics are presented in Table 1 below. 
Table 1: Subject Characteristics and 1-RM Strength Assessment Results. No significant 
differences exist between the BCS and Control groups. 
 BCS (n=4) 
(mean ± SD) 
Controls (n=8) 
(mean ± SD) 
Age (yrs) 60 ± 12 56 ± 7 
Height (cm) 168.6 ± 3.1 163.7 ± 6.8 
Weight (kg) 75.6 ± 13.4 67.2 ± 6.3 
Body Fat (%) 37.6 ± 10.3 37.6 ± 4.5 
1-RM Leg Press (kg) 81.6 ± 20.0 79.5 ± 14.5 
1-RM LPD (kg) 33.2 ± 5.5 35.8 ± 6.8 
1-RM Leg Ext. (kg) 58.4 ± 15.1 60.3 ± 12.5 
1-RM Seated Row (kg) 34.1 ± 5.3 38.8 ± 3.9 
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Table 2: Subject Cancer Treatment Characteristics for BCS Group 
 
 Means and standard deviations for total leukocyte, granulocyte, lymphocyte, and 
monocytes cell counts at each of the four measurement points (baseline, 0h post-exercise, 2h 
post-exercise, and 24h post-exercise) are presented below in Table 3. Immune parameter data 
at 0h post and 24h post-exercise for one control, and at 2h post-exercise for one BCS and one 
control subject were not obtained during the study due to technical measurement errors (i.e. 
blood clotting, catheter malfunction, inability to perform the venipuncture procedure, or 
inability of a subject to return to the lab for the 24h post-exercise blood draw).  Mean 
substitution procedures for the missing measurement data were performed for all variables of 
these subjects. Exploratory analyses on the effects of the acute bout of resistance exercise on 
cortisol were conducted and are also presented in Table 3. Similarly, mean substitution was 
performed for 2 control subjects at all four time points, and one breast cancer survivor at the 
24h post time point.  All reported cell and cortisol values have been adjusted for plasma 
volume shift (PV shift), which is depicted in Table 4. 
 
 
 
 
 
 
 
 
 
 
Treatment Number of Subjects 
(n=4) 
Surgery, Chemotherapy, Hormonal Therapy 2 
Surgery, Chemotherapy, Radiation 1 
Surgery, Chemotherapy, Radiation, 
Hormonal Therapy 
1 
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Table 3: Leukocyte, Leukocyte Subset, and Cortisol Values Adjusted for Plasma Volume 
Shift. 
Variable  Time  BCS (n=4) 
(mean ± SD)  
Controls (n=8) 
(mean ± SD)  
Total Leukocytes 
(cells/uL)  
 
4,800-10,800 
Baseline 
0h Post 
2h Post 
24h Post  
5575.0 ± 1358.0 
6498.3 ± 1460.6* 
6753.1 ± 1619.5* 
5700.5 ± 1003.7  
5166.7 ± 795.3 
5785.1 ± 934.6 
5760.4 ± 686.8 
5426.1 ± 785.6  
Granulocytes 
(cells/uL) 
 
3,100-7,400 
Baseline 
0h Post 
2h Post 
24h Post  
3704.2 ± 1054.4 
4255.3 ± 1040.3* 
4640.3 ± 1193.1* 
3833.6 ± 607.3  
3410.4 ± 476.7 
3819.4 ± 734.2* 
3691.2 ± 652.6 
3609.3 ± 624.2  
Lymphocytes 
(cells/uL) 
 
1,500-3,000 
Baseline 
0h Post 
2h Post 
24h Post  
1479.2 ± 151.2 
1845.5 ± 356.9 
1788.0 ± 433.7 
1310.1 ± 243.5 
1410.4 ± 434.7 
1640.8 ± 371.3 
1745.8 ± 501.8 
1418.6 ± 273.4  
Monocytes 
(cells/uL) 
 
100-700 
Baseline 
0h Post 
2h Post 
24h Post  
395.8 ± 141.7 
398.8 ± 204.9 
325.0 ± 23.2 
589.7 ± 168.2*† 
354.2 ± 152.4 
328.2 ± 146.9 
318.1 ± 118.0 
400.0 ± 108.2  
Cortisol** 
(ng/mL)  
Baseline 
0h Post 
2h Post 
24h Post  
94.36 ± 18.05 
65.18 ± 8.49 
47.58 ± 11.35* 
55.31 ± 14.60  
139.65 ± 67.42 
87.95 ± 36.17 
126.45 ± 108.43 
127.16 ± 82.05 
Paired-samples and independent samples T-tests were performed for the evaluation of 
comparisons between post-exercise values and baseline values within as well as between the 
BCS and control groups at each assessment time. *Denotes statistical significance (p ≤ 0.05) 
when compared to baseline. †Denotes statistical significance (p ≤ 0.05) between BCS and 
control groups. Indicates normal cell ranges under resting conditions (Marieb & Hoehn, 2010). 
**For the cortisol analyses, only data for 6 control and 4 BCS subjects is presented.  
 
Non-parametric analyses were conducted on the cortisol data, since the results were 
unequally distributed. A Mann-Whitney U analysis was conducted to test for between group 
differences, and no statistically significant differences were found (p=0.3938; p=0.6698; 
p=0.0550; p=0.5224 for baseline, 0h post-exercise, 2h post-exercise, and 24h post-exercise, 
respectively).  A Friedman test was used to evaluate within-group differences, and a 
significant difference in cortisol response was found within the breast cancer survivor group 
between baseline and 2h post-exercise (p = 0.0129). 
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Table 4: Mean Hematocrit (Hct) and Hemobglobin (Hb) values with corresponding plasma 
volume changes (Δ % changes) from baseline to 0h post-exercise; baseline to 2h post-
exercise; and baseline to 24h post-exercise. 
 
 
 
HCT (%) 
 
Hb (g/dL) 
 
%∆ 
Baseline 
to 0h 
Post 
 
%∆ 
Baseline 
to 2hr 
Post 
 
%∆ 
Baseline 
to 24hr 
Post  
Base-
line 
 
0h 
Post 
 
2hr 
Post 
 
24hr 
Post 
 
Base-
line 
 
0h 
Post 
 
2hr 
Post 
 
24hr 
Post 
BCS 38.08 39.33 38.00 38.44 11.05 11.23 10.78 11.27 -3.58 2.58 0.91 
Controls 37.92 40.86 38.31 38.83 10.70 11.70 10.52 11.17 -10.53 1.60 -2.95 
 
A mixed-model ANOVA for each of the dependent variables (total leukocytes, 
granulocytes, lymphocytes, and monocytes) using the percent change (% Δ) scores from 
baseline – 0h post-exercise, baseline – 2h post-exercise, and baseline – 24h post-exercise was 
conducted to examine the differences between changes in the breast cancer survivor group 
and changes in the control group. For subjects missing data points, a mean substitution for 
the % ∆ scores of the group was used. Percent ∆ scores were calculated as follows: (% ∆= 0h 
post-exercise count – baseline count/ baseline count x 100; % ∆ = 2h post-exercise count – 
baseline count / baseline count x 100; and % ∆ = 24h post-exercise count – baseline count / 
baseline count x 100, respectively). Results are presented in Table 5 below:  
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Table 5: Percent change (% ∆) scores for total leukocytes, granulocytes, lymphocytes, and 
monocytes depicting the % ∆ from baseline-0h post-exercise, baseline-2h post-exercise, and 
baseline-24h post-exercise. 
 % ∆ Baseline- 
0h Post 
(mean ± SD) 
% ∆ Baseline- 
2h Post 
(mean ± SD) 
% ∆ Baseline- 
24h Post 
(mean ± SD) 
Total Leukocytes BCS 16.98 ± 3.78 21.30 ± 3.65 6.22 ± 6.67 
Controls 15.35 ± 13.01 14.98 ± 19.93 8.10 ± 8.62 
Granulocytes BCS 16.06 ± 7.36 26.30 ± 9.10 9.47 ± 12.65 
Controls 12.44 ± 11.50 12.97 ± 29.57 6.51 ± 11.65 
Lymphocytes BCS 24.50 ± 18.83 19.66 ± 17.58 -11.62 ± 8.16 
Controls 25.54 ± 13.03 28.36 ± 40.37 10.13 ± 16.72 
Monocytes BCS -3.77 ± 21.41 -9.07 ± 33.02 66.28 ± 18.55 
Controls 44.35 ± 159.66 7.29 ± 47.00 61.83 ± 125.19 
 
No significant differences between the breast cancer survivor group and the control 
group were found between the % ∆ scores for any of the dependent variables (total 
leukocytes: p = 0.560; granulocytes: p = 0.239; lymphocytes: p = .257; monocytes: p = 
0.721), indicating that the breast cancer survivor and control groups experienced similar 
percent cell count changes from baseline at 0h, 2h, and 24h following the exercise bout. 
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Chapter V 
 
Discussion 
  
The examination of the effect of an acute bout of resistance training on the immune 
system’s response in breast cancer survivors can provide researchers with important 
information for exercise prescription in a breast cancer population. Since resistance exercise 
has been shown to be a feasible and efficacious method for improving a plethora of 
physiological and psychological parameters in individuals with breast cancer (Cheema et al., 
2008; Courneya et al., 2007; Schmitz et al., 2005; Segal et al., 2009), it is of great importance 
for researchers to determine an exercise protocol designed to optimize these results. Further, 
it is essential that exercise programs for individuals with cancer do not impair the immune 
system because sub-optimal immune function can increase the risk of secondary malignancy 
and illness susceptibility (Hutnick et al., 2005). Although the body of research is small, 
current research in exercise oncology suggests that exercise may serve as a means of 
enhancing immune function in cancer patients, which can improve the chances of disease-
free survivorship (Fairey et al., 2002; Fairey et al., 2005; Hutnick et al., 2005).  
Knowing how the immune systems of breast cancer patients respond to a single bout 
of exercise is imperative to program design for this population. It is essential that secondary 
training sessions are not implemented until the immune system has fully recovered from the 
primary bout. Consistent failure to allot adequate recovery time between subsequent training 
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sessions in exercising individuals is suggested to result in chronic immunosuppression and 
impairment of overall health (Gleeson, 2001; Koch, 2010). Because breast cancer survivors 
often already have impaired immune function as a result of cancer treatments, further 
immunosuppression must be avoided. Since the acute immune response differs between the 
mode, intensity, and duration of exercise bouts (Koch, 2010), the aim of this study was to 
determine how the immune system in breast cancer survivors responded to a single bout of 
moderate-intensity resistance training.  
To the authors’ knowledge, this is the first study to look at the immune response to a 
single bout of resistance training in a breast cancer population. The only other study to 
examine the effects of an acute bout of resistance exercise in cancer patients was a training 
study by Galvao and colleagues in 2008, where the immune response in prostate cancer 
patients was measured during and following a 20 week resistance training program. It is 
important to note that the acute response was not the main outcome variable of this study, as 
the authors’ primary objective was to evaluate the effect of chronic resistance training on 
various endocrine and immune parameters. The results of this study indicated that 
immediately following an acute bout of resistance training, total leukocyte, neutrophil, 
lymphocyte, and monocyte cell counts in the prostate cancer patients responded similarly to 
those of healthy individuals. However, blood samples were not taken into the recovery period 
following the exercise bout. Therefore, the present study is the first to examine the timeline 
of immune response and recovery to an acute resistance training session in cancer patients. 
It should also be noted that the vast majority of the literature reporting the immune 
response to acute exercise is describing the effects of a bout of endurance training, as 
opposed to resistance training. The differences in the immune response to the various 
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exercise modalities even in healthy individuals have not been clearly established (Koch, 
2010). 
Immune Response to Resistance Training in Breast Cancer Survivors 
 
 The following discussion will be broken down into 6 sections. The first section will 
focus on the response from baseline to 0h post-exercise, the second will discuss the response 
from baseline to 2h post-exercise, the third will address the response from baseline to 24h 
post-exercise, the fourth will outline the limitations of the present study, the fifth will present 
concluding statements, and the sixth will provide recommendations for future research. 
Baseline – 0h Post-Exercise 
 
 The immune response from baseline to 0h post-exercise in the BCS group is 
relatively consistent with the current literature in exercise immunology (Gleeson, 2007; 
Pedersen & Hoffman-Goetz, 2000; Walsh et al., 2011). Results indicated a significant 
increase in total leukocytes and granulocytes immediately following the exercise bout. 
Although the subset of granulocytes is comprised of neutrophils, basophils, and eosinophils, 
the majority of circulating granulocytes are made up of neutrophils, which are highly 
responsive to acute exercise (Walsh et al., 2011). Further, neutrophils and lymphocytes 
comprise approximately 60% and 25%, respectively, of all circulating leukocytes , so 
transient changes in these cells will likely be reflected by the overall change in total 
leukocyte count as well (Gleeson, 2007; Marieb & Hoehn, 2010; Pedersen & Hoffman-
Goetz, 2000; Walsh et al., 2011). 
 The neutrophilia observed at 0h post-exercise is likely due to increases in cardiac 
output and sympathetic activity that occurs as a result of exercise. It is widely hypothesized 
that the increases in shear stress that occur as a result of increased cardiac output, coupled 
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with the increased catecholamine secretion that happens upon engaging in physical activity 
cause a demarginalization of neutrophils into the circulation, thereby increasing the numbers 
of circulating neutrophils (Koch 2010; Pedersen & Hoffman-Goetz, 2000, Walsh et al., 
2011). It is known that neutrophils contain a β-adrenergic receptor, which provides the basis 
for support that catecholamines play a partial role in mediating the neutrophil response to 
acute exercise (Pedersen & Hoffman-Goetz, 2000). Although the magnitude of 
catecholamine release was not measured in this study, it is widely accepted that participation 
in physical activity is accompanied by sympathetic nervous system activation and the 
secretion of epinephrine and norepinephrine into the circulation, which is likely a 
contributing factor to the observed neutrophilia. 
 The current research available on the immune response to resistance training is in 
accordance with the present findings, indicating that an acute bout of resistance training 
results in an increase in total leukocyte (Kraemer et al., 2006; Neves Jr. et al., 2009) and 
neutrophil counts (Galvao et al., 2008; Koch, 2010; Ramel et al., 2003) immediately 
following completion of the exercise bout. Although exercise has been shown to increase 
neutrophil mobilization into the circulation, research has suggested that these cells show a 
reduction in their responsiveness to bacterial lipopolysaccharide, which can last for several 
hours and is indicative of impaired functionality (Gleeson 2007; Nieman 1997). Neutrophil 
function was not measured in this study, therefore the capacity of these cells to respond to 
external stimuli following an acute bout of resistance training cannot be commented upon. 
The influence of exercise on lymphocytes in breast cancer patients is of particular 
interest to a variety of researchers, as it has been shown that chemotherapy and radiation 
treatments negatively influence optimal lymphocyte functioning in virtually of the 
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lymphocyte subsets and that optimal lymphocyte function, particularly that of NK cells, is 
related to overall survivorship (Hutnick et al., 2005; Fairey et al., 2002). No significant 
differences were observed in lymphocyte counts from baseline to 0h post-exercise in either 
the BCS or the control group. This is likely due to the nature of the exercise bout performed 
(moderate-intensity, relatively short duration; Nieman, 2003). Although lymphocyte counts 
did not increase significantly in either group, there were modest increases in the number of 
circulating lymphocytes immediately following the exercise bout in both BCS and control 
groups, which likely served as a contributing factor to the increase in total leukocytes 
observed immediately post-exercise. According to the literature, a post-exercise 
lymphocytosis is observed due to the mobilization of these cells from a variety of organs, 
including the spleen, lymph nodes, and gastrointestinal tract (Pedersen & Hoffman-Goetz, 
2000). Post-exercise lymphocytosis is depicted to occur in proportion to exercise intensity 
and duration, with intensity serving as the more prominent mediator of the lymphocyte 
response (Walsh et al., 2011).   
Like neutrophils, T, B, and NK lymphocytes contain β-adrenergic receptors, 
suggesting that these cells are responsive to catecholamine secretion, which is released as a 
result of exercise onset (Pedersen & Hoffman-Goetz, 2000; Walsh et al., 2011). This is 
demonstrated by the fact that NK cells contain the greatest concentration of β-adrenergic 
receptors, followed by CD8+ T-cells and B-cells, and finally CD4+ T-cells. It is known that 
NK cells are the most responsive lymphocyte subpopulation to an acute bout of exercise, 
followed by CD8+ cells and B-cells, and that CD4+ cells are the least responsive, which 
suggests the powerful role of catecholamines in influencing the lymphocyte response to 
exercise (Pedersen & Hoffman-Goetz, 2000; Walsh et al., 2011). It is speculated that 
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catecholamines initiate a down-regulation in adhesion molecule expression on endothelial 
cell walls (Walsh et al., 2011). As neither catecholamines or the specific lymphocyte subsets 
were measured as part of the present study, the magnitude of catecholamine secretion and its 
potential effect on the lymphocyte response cannot be commented upon. 
Although derived primarily from studies examining the immune response to aerobic 
exercise, the upregulation of lymphocyte counts is supported in the study by Simonson and 
Jackson in 2004. This study demonstrated that the transient increase in the concentration of 
circulating lymphocytes immediately following an acute bout of resistance training was due 
primarily to increases in NK cell count, with less pronounced upregulation of CD8+ and 
CD4+ subsets. Conversely, Kraemer et al. (1996) and Neves Jr et al. (2009) did not report a 
significant increase in the numbers of circulating lymphocytes immediately following a 
single bout of resistance training in either healthy men or older women, respectively. This 
disparity in the lymphocyte response to resistance training may be related to the rest intervals 
allotted between subsequent exercises, but more research is needed to explore this possibility 
Therefore, the lymphocyte response to resistance training specifically remains controversial. 
No significant difference in monocyte concentration was noted from baseline to 0h 
post-exercise in either the BCS or control groups. This appears to contrast with the current 
literature, which reports increases in monocyte counts in response to a single bout of 
resistance training (Galvao et al., 2008; Simonson & Jackson, 2004). The mechanism for 
post-exercise monocytosis is suggested to be in line with that of neutrophils and 
lymphocytes, with increases in cardiac output, hemodynamic alterations, and catecholamines 
playing a mediating role. It is speculated that these factors result in a demargination of 
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monocytes into the circulation partially due to manipulation of the monocyte-endothelial 
interaction (Woods et al., 2000; Walsh et al., 2011).  
Further, it is known that exercise affects the phenotype, cytokine expression, and cell 
surface proteins of circulating monocytes. Monocytes are responsible for secreting a variety 
of cytokines into the circulation. Also, monocytes can be classified as classical or as pro-
inflammatory, which differ in their physiological function (Gleeson et al., 2011; Simpson et 
al., 2009). It has been shown that aerobic exercise results in an increase of the pro-
inflammatory type of monocytes into the circulation (Gleeson et al., 2011; Simpson et al., 
2009). However, the clinical significance of exercise-induced changes in circulating 
monocyte counts has yet to be established, as monocytes are immature cells that ultimately 
become tissue macrophages (Walsh et al., 2011). It has not yet been determined whether 
changes in monocyte characteristics reflect changes within bodily tissues, nor whether they 
respond similarly to resistance training (Koch, 2010; Walsh et al., 2011). 
Existing literature on the monocyte response to an acute bout of resistance training is 
relatively scarce. In the study by Simonson and Jackson (2004), there was a significant 
increase in monocytes immediately post-exercise. Further, Galvao and colleagues in 2008 
saw a non-significant increase in monocytes following an acute bout of resistance training in 
prostate cancer patients at the halfway point of their 20-week exercise intervention, but a 
significant increase in circulating monocyte count following a single bout of resistance 
training at week 20. The properties of the monocytes in circulation before and following 
exercise in these, as well as the present, studies were not determined; therefore the 
importance of these exercise-induced changes in overall monocyte counts cannot be inferred.  
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It is known that cancer and its treatments interfere with the function of the 
hypothalamic-pituitary-adrenal axis (HPA axis; Bower, 2007). Therefore, many breast cancer 
survivors experience a disruption in the diurnal variations of cortisol even several years after 
completing treatment. Specifically, breast cancer survivors exhibit blunted diurnal variations 
in cortisol when compared to healthy counterparts, as their daily cortisol fluctuations are 
much less pronounced even at rest (Bower, 2007). As both BCS and controls experienced a 
modest, non-significant reduction in cortisol at 0h post-exercise, it is therefore assumed that 
the exercise session was not of a great enough intensity or duration to stimulate cortisol 
secretion. 
Baseline – 2h Post-Exercise 
 
 Two hours into the recovery period following the acute bout of resistance training, 
total leukocytes and granulocytes were significantly elevated from baseline in the BCS group 
only, and not the control group. At the 2h post-exercise time point, the BCS group continued 
to undergo an upregulation in total leukocytes and granulocytes, whereas the control group 
began to plateau, or drop closer to baseline. The continued increase in granulocytes 2h into 
recovery, which is likely reflected by increases in neutrophils, is somewhat surprising as 
delayed secondary neutrophilia following an acute bout of exercise is typically attributed to 
an exercise-induced rise in cortisol (Walsh et al., 2011). However, cortisol actually decreased 
as a result of the exercise bout and continued to decrease 2h into recovery, reaching a 
significant reduction from baseline in the BCS group at the 2h post-exercise time point. This 
suggests that the delayed neutrophilia observed in the BCS group may be either a continued 
response to the exercise / catecholamine induced primary neutrophilia or that it may be 
attributed to an alternate mechanism, perhaps specific to a breast cancer survivor population. 
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 There were no significant changes from baseline and 2h post-exercise lymphocyte 
counts as a result of the single bout of resistance training in either the BCS or the control 
groups. However, the depiction of the lymphocyte response indicates a trend towards 2h 
post-exercise lymphocytosis in the control group, but a blunted response, or a slight 
reduction in lymphocytisis in the BCS group. The literature, the majority of which focuses on 
the effects of endurance training on the acute immune response, consistently reports a 
reduction in circulating lymphocytes below baseline when exercising individuals enter the 
recovery period, which can last up to several hours post-exercise (Gleeson, 2007; Nieman et 
al., 1991; Pedersen & Hoffman-Goetz, 2000; Walsh et al., 2011). Interestingly, in the study 
by Nieman and colleagues (1991), where healthy female subjects walked on the treadmill at 
the moderate intensity of 60% of VO2max, lymphocytes increased significantly immediately 
post-exercise, dropped slightly below baseline values (though non-significantly) at 1.5h post-
exercise, and then returned to slightly elevated levels at both 3h and 5h into the recovery 
period. While this differs from the present study in exercise modality (aerobic vs. resistance), 
the moderate intensity of the exercise performed is similar between the studies. Because in 
the present study bloods were sampled at 0h and 2h post-exercise it is possible that due to 
infrequency of sampling, we might have missed the biphasic drop in lymphocytes that was 
seen in the study by Nieman (1991) where more frequent blood sampling took place. 
The response of the control group mirrors that of participants in the study by Neves 
Jr. et al. (2009) whereby older women performed a single bout of resistance training at either 
50% of 1-RM or 80% of 1-RM and both groups experienced a significant lymphocytosis 3h 
after the completion of the exercise bout. In the present study, although the control group 
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appeared to exhibit an upwards trend in the number of circulating lymphocytes at 2h into the 
recovery period, the lymphocytosis was non-significant.  
In the BCS group, circulating lymphocytes appear to peak at 0h post exercise, and 
begin to decline at 2h post exercise. Typically, post-exercise lymphocytopenia is attributed to 
the migration of lymphocytes from the circulation into the tissues and/or increases in 
apoptosis resulting in lymphocyte reduction via programmed cell death (Koch, 2010; Walsh 
et al., 2011). Because the literature on the immune response to resistance training is so 
scarce, possible mechanisms for prolonged or blunted lymphocytosis without 
lymphocytopenia into the recovery period from exercise are unknown. Further, the function 
and proliferative capacity of these cells several hours following resistance training are also 
unknown.  
 Monocytes in both BCS and control group appear to be reduced (though non-
significantly) at 2h into the recovery period, which appears to contrast with the present 
literature, which depicts a 2h post-exercise monocytosis (Walsh et al., 2011). The clinical 
significance of this change is not known, as it has been established that exercise alters cell 
surface receptor expression in monocytes, which affect the role that these cells play in 
immunity (Simpson et al., 2009). Without knowing the properties of these cells, the 
implications for breast cancer survivors cannot be inferred. 
 The BCS group experienced a further, significant reduction of cortisol compared to 
baseline values 2h into the recovery period, whereas the cortisol concentration in the control 
group moved back towards baseline. Because the HPA axis appeared not to be stimulated to 
initiate cortisol secretion as evidenced by the absence of cortisol elevations 0h post-exercise, 
it is likely that the response of cortisol in both groups was due to diurnal variation. As 
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previously discussed, the diurnal rhythm of cortisol in breast cancer survivors is oftentimes 
altered from that of healthy women (Bower, 2007), which serves as a possible explanation 
for the significant reduction in cortisol within the BCS group 2h post-exercise. However, 
diurnal variation of cortisol was not controlled for in the present study. 
Baseline – 24h Post-Exercise 
 
 The 24h post-exercise blood sample served as a major component in the present study 
to assist future researchers in establishing more optimal program design for breast cancer 
survivors. While the results of this study indicated no significant difference from baseline in 
any of the measured immune and hormonal parameters, it provided us with insight into 
certain trends that future research should attempt to explore. The return of immune 
parameters to baseline values 24h following the acute bout of resistance training would 
suggest that the immune systems of the participants had adequately recovered from the 
primary bout, and that from an immunological standpoint, it would be physiologically safe to 
implement a secondary training bout 1 day following the first. 
 However, upon closer look, there are several factors that should be examined further 
before such conclusions can be drawn. It appears that the peripheral blood mononuclear cells 
(lymphocytes and monocytes) in the BCS group differ slightly from that of the controls in 
their pattern of response to the resistance exercise bout. The mean %∆ score from baseline – 
24h post-exercise in the BCS group was -11.62%, whereas it was +10.13 for the control 
group, indicating that at 24h post exercise, the lymphocyte count was below baseline in the 
BCS group and above baseline in the control group. Although not statistically significant, 
this disparity between the groups may be of clinical significance. The fact that the 
lymphocyte count in the BCS group is below baseline at 24h post-exercise while the healthy 
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controls are above baseline suggests that perhaps the BCS group may not have sufficiently 
recovered from the primary exercise bout, though a larger sample size is needed to support or 
refute this statement. 
 Similarly, monocyte counts 24h post-exercise in the BCS group are both significantly 
higher than baseline values, and they are significantly greater than that of the controls. As 
previously discussed, monocyte cells can be further broken down into classical monocytes, or 
pro-inflammatory monocytes, which determines the effect that these cells exert on the living 
host (Gleeson et al., 2011; Simpson et al., 2009). The type of monocytes in the circulation of 
the BCS groups at 24h post-exercise was not determined and therefore cannot be addressed 
in this discussion. However, it may be of importance to note that while the clinical 
significance of significantly elevated monocytes 24h post-exercise in the BCS group was not 
determined, the results suggest that this subset of circulating leukocytes is significantly 
deviated from baseline values, adding to the possibility that the BCS group had not fully 
recovered from the exercise bout. 
 Current consensus in exercise immunology suggests that the period of 
immunosuppression, or a reduction in the number and/or function of circulating immune 
parameters can last anywhere between 3 and 72 hours following an acute bout of exercise 
(Pedersen 1999). Further, it is suggested that moderate-intensity exercise results in a positive 
immune response, observed by the absence of significant stress hormone release and a lack 
of pro-inflammatory cytokine secretion (Nieman, 2003). The immune response to moderate-
intensity exercise, as compared to high intensity exercise, is thought to exhibit transient 
upregulations in the various immune parameters in an absence of significant 
immunosuppression of these parameters (Nieman, 2003). The trend towards lymphocyte 
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suppression in the BCS group 24h post-exercise suggests that breast cancer survivors, who 
are thought to have altered immune parameters as a result of cancer and its treatments may 
respond differently to moderate-intensity exercise than healthy, age-matched controls. It is 
possible that even moderate-intensity exercise for a cancer population is perceived as a 
greater physiological stressor than in a healthy individual of the same age. 
Limitations of the Study 
 
 There were some limitations to the present study. Perhaps the most prominent is the 
small sample size that was recruited for participation, consisting of 8 control subjects and 
only 4 BCS. Additionally, it is possible that some subjects who participated in the study were 
more physically fit than others, and training status is known to influence the acute immune 
response to exercise (Koch, 2010). The immune and inflammatory response to resistance 
exercise in individuals who are trained is known to be less pronounced than in those who are 
untrained, particularly upon secondary exposure to a similar resistance exercise routine 
(known as the ‘repeated bout effect’; Koch, 2010).  However, this particular influence was 
likely minimized as all participants within this study were unfamiliar with the 4 resistance 
exercises used for the resistance training protocol. Another potential limitation to the present 
study is the time since treatment completion for subjects in the BCS group. The time since 
chemotherapy completion ranged from 4 months up to 1 year within the 4 BCS subjects. It is 
possible that the participants closer to treatment completion were experiencing more 
prominent treatment-related immune effects that those farther out from treatment (Fairey et 
al., 2002). It is a possibility that these differences were exacerbated by the small sample size. 
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Conclusion 
 
 It is known that cancer and its treatments are accompanied by negative alterations in 
the immune system, which can persist several years following the completion of treatment 
(Hutnick et al., 2005). However, it is possible that exercise may serve as a means of 
enhancing immune function in cancer survivors (Fairey et al., 2005; Hutnick et al., 2005). 
Exercise programs designed around the complete recovery of immune parameters from a 
primary exercise bout before the implementation of secondary exercise bout serve to ensure 
that participants do not experience chronic immunosuppression that is associated with 
overtraining (Gleeson, 2002). In a breast cancer survivor population, this concept is 
important in program design, as exercise programs geared towards this population are aimed 
at improving functional capacity, overall quality of life, and survivorship. 
 The results of this study suggest that breast cancer survivors and healthy age-
matched controls respond similarly to an acute bout of resistance training. In other words, the 
changes in total leukocyte, granulocyte, lymphocyte, and monocyte cell counts from baseline 
to 0h post-exercise, baseline to 2h post-exercise, and baseline to 24h post-exercise in the 
BCS and healthy control groups were not statistically different from each other. However, 
this response warrants further investigation before conclusions can be made. Regardless, the 
present study serves as the foundation for future research to examine the immune response to 
an acute bout of resistance exercise in breast cancer patients. 
Recommendations for Future Research 
 
 Although this was a small-scale study, it was the first one to examine the effects of an 
acute bout of resistance training on leukocyte and leukocyte subset response in breast cancer 
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survivors. As such, the results of the present study generated a wide array of questions that 
future research should aim to answer.  
Firstly, the present study should be repeated with a larger sample size to confirm the 
nature of the immune response in both the BCS and the healthy age-matched controls. 
Secondly, future studies should aim to recruit a more homogenous sample in regards to time 
since last chemotherapy treatment in the BCS group and physical activity level in both 
groups. Thirdly, future research should aim to stratify the various leukocyte subsets further, 
to get a better idea as to how the exercise affected the cellular immune response, particularly 
that of the lymphocytes and monocytes, which can be classified into cells with drastically 
different phenotypes.  Once these have been done, if the results (a similar immune response 
in BCS and healthy controls) hold true, future studies should aim to examine the effects of 
multiple exercise bouts over the course of several days on immune parameters in breast 
cancer patients and healthy controls.  
Finally, the functionality of the circulating cells should be examined to determine the 
influence of resistance exercise on the ability of the immune system to respond to external 
stimuli and prevent infection. Future research should attempt to explore the clinical 
significance of alterations in the circulating immune parameters, as many immune 
components act outside of the circulation in the lymph and bodily tissues. 
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Appendix A 
 
University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study 
Adult Subjects:  Breast Cancer Survivor Group 
Biomedical Form 
________________________________________________________________________ 
 
IRB Study # 11-1405 
Consent Form Version Date:  January 10, 2013 
 
Title of Study: The Impact of Acute Aerobic and Resistance Exercise on Natural Killer Cell, 
Catecholamine, and Cortisol Responses in Breast Cancer Survivors 
 
Principal Investigator: Claudio L. Battaglini, PhD 
UNC-Chapel Hill Department:  Exercise & Sport Science 
UNC-Chapel Hill Phone number: 843-6045 
Email Address: claudio@email.unc.edu 
Co-Investigators: Elizabeth S. Evans, MA; Anthony C. Hackney, PhD, DSc; Robert G. 
McMurray, PhD; Hyman B. Muss, MD; Scott H. Randell, PhD; Rachel Graff, BS; Jacob 
Allen, BA; Miles Bartlett, MA; Nathan Berry, MA; Jamie Pearson, BS; Charlotte Shatten 
MA; Ryan Vanhoy, BS; Jeremiah Boles, MD; Mingqing Li, MD; Amy Lucas, MD; Autumn 
Mcree, MD; Payal Desai, MD; Christine Lin, MD; Marshall Mazepa, MD; Micah Mooberry, 
MD; Ryan Raddin, MD; Tyler Buckner, MD; Andrea Dean, MD; Satish Gopal, MD; Emily 
Jenkins, MD; Adam Kuykendal, MD; Keeran Sampat, MD 
 
Funding Source and/or Sponsor: NA 
 
Study Contact telephone number:  (516) 633-5235 or (919) 621-1322 
Study Contact email:  rgraff1@email.unc.edu or jmallen@email.unc.edu 
_________________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary.  
You may refuse to join, or you may withdraw your consent to be in the study, for any reason. 
 
Research studies are designed to obtain new knowledge that may help other people in the 
future.  You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. 
 
Deciding not to be in the study or leaving the study before it is done will not affect your 
relationship with the researcher, your health care provider, or the University of North 
Carolina-Chapel Hill.  If you are a patient with an illness, you do not have to be in the 
research study in order to receive health care.  
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Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
You will be given a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study?  
The purpose of this research study is to learn about the effect of one session of moderate 
intensity aerobic or resistance exercise on the immune system and endocrine system of breast 
cancer survivors.  The immune system helps to protect the body from getting sick.  The 
endocrine system includes the hormones that the body makes, some of which can affect the 
immune system.  We will also be examining how the same type of aerobic or resistance 
exercise affects age-matched women who have never experienced cancer treatment.   
 
Over the past 20 years, regular aerobic and resistance exercise has been shown to improve 
the health and well-being of breast cancer survivors in many different ways.  Regular 
participation in exercise can help decrease feelings of fatigue, anxiety, and depression.  
Regular aerobic and resistance exercise can also help improve physical fitness, build strong 
bones and muscles, and lower the amount of fat stored in the body.  Regular moderate 
aerobic or resistance exercise may also improve the immune system’s ability to fight 
infections, and it may also lower the body’s production of stress hormones.  However, 
researchers still have many questions to answer regarding how aerobic exercise and 
resistance exercise affect the immune system and stress hormone levels in breast cancer 
survivors, especially when compared to healthy age-matched women who have never 
experienced treatment for cancer.   
 
The primary aim of this study is to examine the effects of a moderate-intensity, 30-minute 
aerobic exercise bout or a moderate-intensity resistance exercise bout on the natural killer 
(NK) cell.  The NK cell is an important part of the immune system that helps to destroy 
viruses and tumor cells.  Secondly, the affect of these exercise bouts on the stress hormones 
epinephrine, norepinephrine, and cortisol will be examined.  Thirdly, the relationships 
between the response of the NK cell and the response of the stress hormones will be 
measured.  The levels of these markers will be measured immediately before exercise, 
immediately after exercise, 2 hours post-exercise, and 24 hours post-exercise via blood 
samples. 
 
Why are you being asked to participate in this study? 
You are being asked to be in the study because you are a woman who has been diagnosed 
with breast cancer, you have completed surgery, chemotherapy, and radiation therapy within 
the past 3-6 months, and you are between the ages of 40 and 70 years.  The full list of 
inclusion criteria for participation in this study are listed below:  
3.1.1. Confirmed diagnosis of Stage I, II, or III invasive breast cancer; 
3.1.2. Must have received chemotherapy; 
3.1.3.  Must have completed surgery, chemotherapy, and radiation therapy 3-6 months prior 
to enrollment; 
3.1.4. Patients receiving adjuvant hormonal therapy or adjuvant trastuzumab are eligible; 
3.1.5. No presence of metastatic disease; 
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3.1.6. Female, between 40 and 70 years of age; 
3.1.7. Not involved in regular organized physical activity for at least 1 year prior to 
enrollment, meaning that you exercise less than 3 times per week and that you do not 
engage in activities of moderate or vigorous intensity. 
3.1.8. Not taking any anti-inflammatory medications; 
3.1.9. Clearance from your oncologist to participate in exercise. 
 
Are there any reasons you should not be in this study? 
You should not be in this study if you have any type of disease that affects your heart, lungs, 
bones, or muscles which would make it very difficult for you to exercise. You should not be 
in this study if you have uncontrolled diabetes or thyroid disease.  You should not be in this 
study if you have had a fever, body aches, and/or swollen glands within the past 6 weeks or if 
you have a chronic infectious disease such as hepatitis or AIDS.  You should not be in this 
study if you have abnormally low values for certain blood markers, including potassium, 
magnesium, white blood cells, hematocrit, and platelets.  Also, you should not be in this 
study if you are currently using an anti-inflammatory medication such as non-steroidal anti-
inflammatory drugs (NSAIDs) or glucocorticoids, or you have any other mental or physical 
impairment that would prevent you from being able to exercise. 
 
How many people will take part in this study? 
If you decide to be in this study, you will be one of approximately 40 people in this research 
study. 
 
How long will your part in this study last?  
You will be asked to come to the laboratory for 3 separate visits.  Laboratory Visit 1 will last 
approximately 2 hours, Laboratory Visit 2 will last approximately 3 hours, and Laboratory 
Visit 3 will last approximately 30 minutes.  The overall length of time that you will 
participate in the study will be approximately 1-2 weeks, but may be shorter. 
 
As this study involves drawing blood, some of your blood samples may be frozen and stored 
indefinitely for future analyses.  You will be given a separate consent form describing 
storage of the blood samples. 
 
What will happen if you take part in the study? 
Participation in this study will require you to report to the laboratory for 3 separate visits.  All 
Laboratory Visits will take place in the Integrative Exercise Oncology Research Laboratory 
(IEORL), which is located in Fetzer Hall, in the Department of Exercise and Sport Science at 
UNC-Chapel Hill.  All study procedures are a requirement of participation in the study. 
 
Laboratory Visit 1: Orientation / Familiarization to the Study and 1-RM Assessment 
(Resistance Exercise Group Only) 
The purpose of Laboratory Visit 1 is to provide you with an overview of the study, give you 
an opportunity to ask questions about your participation, sign this informed consent, gather 
some demographic information about you, and to assess your muscular strength.  The 
specific procedures that will be performed are listed below: 
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1. Sign informed consent documents 
2. Fill out a medical history questionnaire  
3. Undergo a brief medical and physical screening, including a resting 
electrocardiogram (ECG) to measure heart function 
4. Undergo body composition analysis to assess percent body fat using a DEXA 
5. Familiarization with equipment used during exercise testing 
6. Undergo an exercise test to assess muscular strength 
 
The purposes of items 2, 3, and 4, are to determine if it is safe for you to participate in 
exercise and to gain some demographic information about you, including your age, height, 
weight, percent body fat, race, physical activity participation over the past year, and type of 
cancer treatments you have received and are currently receiving. The machine that will be 
used to measure your percent body fat in item 4 is called a DEXA.  DEXA stands for Dual 
Energy X-ray Absorptiometry.  The DEXA uses two x-ray beams to measure differences in 
the composition of different tissues in your body, such as bones, soft tissue, and fat.  The 
scan is performed while you rest on your back, and takes approximately 6 minutes.   
 
The purpose of item 6 is to perform an exercise assessment that will allow the researchers to 
determine your muscular strength, or the greatest amount of weight that certain muscle 
groups can lift one time.  This exercise assessment will involve performing 4 different 
exercises. They are: leg press, lateral pull down, leg extension, and seated row. The exercise 
assessment will involve a series of one-repetition trials with increasing workloads until you 
decide that the given weight is the most that you can lift with proper form. This will be done 
for each of the 4 exercises. The duration of the exercise assessment will likely last no more 
than 30 minutes. 
Laboratory Visit 2: Acute Resistance Exercise Session (Resistance Exercise Group Only) 
Laboratory Visit 2 will occur between 7-14 days of Laboratory Visit 1.  During this Visit, 
you will be performing 1 session of moderate-intensity resistance exercise on the same 4 
pieces of equipment used in Laboratory Visit 1 (leg press, lateral pull down, leg extension, 
and seated row).  This will be the exercise bout that will be used to elicit a response in your 
immune cells, inflammatory markers, and stress hormones.  The specific procedures that will 
be performed are listed below: 
 
1. Fill out a psychological stress questionnaire 
2. Pre-exercise blood sample 
3. Moderate-intensity resistance exercise session 
4. Post-exercise blood sample (immediately post-exercise) 
5. Post-exercise blood sample (2 hours post-exercise) 
 
The purpose of item 1 is to determine if you are feeling any emotional or psychological stress 
on the day of testing.  This is important information as the levels of stress hormones in your 
blood may be influenced by emotional or psychological stress. 
 
During item 3, you will be performing an approximately 30-minute bout of moderate-
intensity resistance exercise on the leg press, lateral pull down, leg extension, and seated row.  
A moderate intensity level of exercise will make you feel like your muscles are working, but 
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you are able to carry on a conversation.  You will alternate between each of the four 
resistance exercises, performing 10 repetitions of each followed by 1.5 minutes of rest before 
continuing on to the next exercise. You will move from the leg press to the lateral pull down 
to the leg extension to the seated row, with the same number of repetitions and amount of rest 
until you have completed each exercise three times.  
 
The 3 blood samples to be obtained during items 2, 4, and 5 will be performed by using a 
small catheter inserted into a vein in your arm.  This blood sampling procedure is very 
similar to a blood sampling procedure that is used in routine medical clinic settings.  
Approximately 1 tablespoon of blood will be collected for each item.  Some of this blood 
will be used during the course of this study to measure the number of NK cells in your blood, 
the activity of the NK cells (i.e., how well they destroy other cells), and the levels of stress 
hormones and cytokines in your blood.   
 
Laboratory Visit 3:  24-hour Follow-up Session  
 
Laboratory Visit 3 will occur 24 hours after Laboratory Visit 2.  During this Visit, you will 
answer the same psychological stress questionnaire as you did in the previous laboratory 
visit.  You will also have 1 blood sample drawn, which will also be used to the number of 
NK cells in your blood, the activity of the NK cells (i.e., how well they destroy other cells), 
and the levels of stress hormones and cytokines in your blood.  The procedure for obtaining 
the blood sample is the same as described above, except that the blood will be drawn through 
a small needle instead of a catheter. 
 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. The benefits to you from 
being in this study may be the opportunity to have your various aspects of your health 
assessed during Laboratory Visit 1.  This would include looking at how well your heart is 
working by using the ECG and by listening to your heart with a stethoscope.  Additionally, 
you will have your muscular strength assessed, as well as your percent body fat.  This 
information may be useful if you are be thinking of beginning an exercise program, and you 
may elect to provide this information to an exercise specialist who could construct and 
supervise an individualized exercise program for you. 
 
What are the possible risks or discomforts involved with being in this study?  
The risk of physiological and psychological harm is very minimal and would not cost you 
physical or emotional loss.  However, any research study does carry with it some potential 
for risk or discomfort, listed below:  
 
1. During Laboratory Visit 1, you will be performing an exercise test to determine your 
muscular strength.  The test will start with an easy warm-up and movement rehearsal 
for your muscles. As the one repetition maximum trials begin, you will find that the 
assessment will become more difficult.  It is possible that increased stress will be 
placed on your musculoskeletal system.  To ensure your safety, your heart rate and 
your lifting technique will be monitored continuously throughout the various trials to 
verify that there are no movement compensations. Your heart rate will continue to be 
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monitored for several minutes after the conclusion of the one repetition maximum 
assessments. At the conclusion of the test, you will be allowed to cool down, stretch, 
and drink water at liberty.   
 
2. During Laboratory Visit 1, you will be exposed to radiation during the DEXA scan.  
However, the scan itself is very safe, and the amount of x-ray radiation that you will 
receive during the scan is 0.8 mrems, which is extremely small.  To put this in 
perspective, this amount of radiation is about the same amount of radiation that you 
would receive from natural background sources in one day. 
 
3. During Laboratory Visits 1 and 2, it is possible that you could experience slight 
muscle or joint soreness after the exercise.  However, this soreness would not be any 
worse than after doing any other type of exercise.  To minimize the amount of 
soreness you might feel, you will be allowed to stretch before and after exercise, and 
you will be allowed to do a light warm-up and cool-down before and after exercise. 
 
4. During Laboratory Visits 2 and 3, it is possible that you could experience some mild 
bruising or discomfort while having your blood drawn.  This discomfort would not be 
any more significant than having your blood drawn at the doctor’s office.  The blood 
sampling procedures will be performed by research team members who have drawn 
blood many times before, and proper bandaging will be performed to minimize 
bleeding. 
 
In addition, there may be uncommon or previously unknown risks that might occur.  You 
should report any problems to the researchers. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might 
affect your willingness to continue your participation.   
 
How will your privacy be protected?   
You will not be identified in any report or publication about this study. Although every effort 
will be made to keep research records private, there may be times when federal or state law 
requires the disclosure of such records, including personal information.  This is very unlikely, 
but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to 
protect the privacy of personal information.  In some cases, your information in this research 
study could be reviewed by representatives of the University, research sponsors, or 
government agencies (for example, the FDA) for purposes such as quality control or safety.    
 
All data obtained from you during this study will be coded using a research ID number, and 
only the members of the research team will have access to these codes.  Study databases and 
logs will not have any information that will allow for subjects to be identified by anyone 
other than a research team member.   
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A copy of this consent form will go in to your medical record.  This will allow the doctors 
caring for you to know what study tests you may be receiving as a part of the study and know 
how to take care of you if you have other health problems or needs during the study. 
 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  This may include 
the risk of personal injury. In spite of all safety measures, you might develop a reaction or 
injury from being in this study. If such problems occur, the researchers will help you get 
medical care, but any costs for the medical care will be billed to you and/or your insurance 
company. The University of North Carolina at Chapel Hill has not set aside funds to pay you 
for any such reactions or injuries, or for the related medical care. However, by signing this 
form, you do not give up any of your legal rights. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have 
the right to stop your participation at any time. This could be because you have had an 
unexpected reaction, you become ill, you use a medication that may affect the outcome of the 
study variables being measured, you are not able to complete the exercise testing sessions, 
you refuse to have your blood drawn, you miss a Laboratory Visit, or because the entire 
study has been stopped.  If you decide to withdraw from the study, all data collected from 
you will be destroyed and will not be used in any data analyses that may result from this 
study. 
 
Will you receive anything for being in this study? 
You will be provided with a written report of your fitness level and percent body fat, both of 
which will be measured during Laboratory Visit 1.   
 
Will it cost you anything to be in this study? 
It will not cost you anything to participate in this study. 
 
What if you are a UNC student? 
You may choose not to be in the study or to stop being in the study before it is over at any 
time.  This will not affect your class standing or grades at UNC-Chapel Hill.  You will not be 
offered or receive any special consideration if you take part in this research. 
 
What if you are a UNC employee? 
Taking part in this research is not a part of your University duties, and refusing will not affect 
your job.  You will not be offered or receive any special job-related consideration if you take 
part in this research. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, complaints, concerns, or if a research-related injury occurs, 
you should contact the researchers listed on the first page of this form.  
 
What if you have questions about your rights as a research subject? 
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All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare.  If you have questions or concerns about your rights as a research subject, 
or if you would like to obtain information or offer input, you may contact the Institutional 
Review Board at 919-966-3113 or by email to IRB_subjects@unc.edu. 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
Title of Study: The Impact of Acute Aerobic and Resistance Exercise on Natural Killer Cell, 
Catecholamine, and Cortisol Responses in Breast Cancer Survivors 
 
Principal Investigator: Claudio L. Battaglini, PhD 
 
Subject’s Agreement:  
 
I have read the information provided above.  I have asked all the questions I have at this time.  
I voluntarily agree to participate in this research study. 
 
_________________________________________________ __________________ 
Signature of Research Subject  Date 
 
_________________________________________________ 
Printed Name of Research Subject 
 
_________________________________________________ __________________ 
Signature of Research Team Member Obtaining Consent  Date 
 
_________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
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Appendix B 
 
University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study 
Adult Subjects:  Healthy Control Group 
Biomedical Form 
________________________________________________________________________ 
 
IRB Study # 11-1405 
Consent Form Version Date:  January 10, 2013 
 
Title of Study: The Impact of Acute Aerobic and Resistance Exercise on Natural Killer Cell, 
Catecholamine, and Cortisol Responses in Breast Cancer Survivors 
 
Principal Investigator: Claudio L. Battaglini, PhD 
UNC-Chapel Hill Department:  Exercise & Sport Science 
UNC-Chapel Hill Phone number: 843-6045 
Email Address: claudio@email.unc.edu 
Co-Investigators: Elizabeth S. Evans, MA; Anthony C. Hackney, PhD, DSc; Robert G. 
McMurray, PhD; Hyman B. Muss, MD; Scott H. Randell, PhD; Rachel Graff, BS; Jacob 
Allen, BA; Miles Bartlett, MA; Nathan Berry, MA; Jamie Pearson, BS; Charlotte Shatten 
MA; Ryan Vanhoy, BS; Jeremiah Boles, MD; Mingqing Li, MD; Amy Lucas, MD; Autumn 
Mcree, MD; Payal Desai, MD; Christine Lin, MD; Marshall Mazepa, MD; Micah Mooberry, 
MD; Ryan Raddin, MD; Tyler Buckner, MD; Andrea Dean, MD; Satish Gopal, MD; Emily 
Jenkins, MD; Adam Kuykendal, MD; Keeran Sampat, MD 
 
Funding Source and/or Sponsor: NA 
 
Study Contact telephone number:  (516) 633-5235 or (919) 621-1322 
Study Contact email:  rgraff1@email.unc.edu or jmallen@email.unc.edu 
_________________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary.  
You may refuse to join, or you may withdraw your consent to be in the study, for any reason. 
 
Research studies are designed to obtain new knowledge that may help other people in the 
future.  You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. 
 
Deciding not to be in the study or leaving the study before it is done will not affect your 
relationship with the researcher, your health care provider, or the University of North 
Carolina-Chapel Hill.  If you are a patient with an illness, you do not have to be in the 
research study in order to receive health care.  
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Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
You will be given a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study?  
The purpose of this research study is to learn about the effect of one session of moderate 
intensity aerobic or resistance exercise on the immune system and endocrine system of breast 
cancer survivors.  The immune system helps to protect the body from getting sick.  The 
endocrine system includes the hormones that the body makes, some of which can affect the 
immune system.  We will also be examining how the same type of aerobic or resistance 
exercise affects age-matched women who have never experienced cancer treatment.   
 
Over the past 20 years, regular aerobic and resistance exercise has been shown to improve 
the health and well-being of breast cancer survivors in many different ways.  Regular 
participation in exercise can help decrease feelings of fatigue, anxiety, and depression.  
Regular aerobic and resistance exercise can also help improve physical fitness, build strong 
bones and muscles, and lower the amount of fat stored in the body.  Regular moderate 
aerobic or resistance exercise may also improve the immune system’s ability to fight 
infections, and it may also lower the body’s production of stress hormones.  However, 
researchers still have many questions to answer regarding how aerobic exercise and 
resistance exercise affect the immune system and stress hormone levels in breast cancer 
survivors, especially when compared to healthy age-matched women who have never 
experienced treatment for cancer.   
 
The primary aim of this study is to examine the effects of a moderate-intensity, 30-minute 
aerobic exercise bout or a moderate-intensity resistance exercise bout on the natural killer 
(NK) cell.  The NK cell is an important part of the immune system that helps to destroy 
viruses and tumor cells.  Secondly, the affect of these exercise bouts on the stress hormones 
epinephrine, norepinephrine, and cortisol will be examined.  Thirdly, the relationships 
between the response of the NK cell and the response of the stress hormones will be 
measured.  The levels of these markers will be measured immediately before exercise, 
immediately after exercise, 2 hours post-exercise, and 24 hours post-exercise via blood 
samples. 
 
Why are you being asked to participate in this study? 
You are being asked to be in the study because you are a woman who has never been 
diagnosed with or treated for cancer, you are post-menopausal, you are sedentary, and you 
are between the ages of 40 and 70 years.  The full list of inclusion criteria for participation in 
this study are listed below: 
3.1.10. Female, between 40 and 70 years of age; 
3.1.11. No history of cancer diagnosis or treatment; 
3.1.12. No presence of any bone, muscle, or other medical condition that would prevent you 
from being able to participate in resistance exercise; 
3.1.13. Not taking anti-inflammatory medications such as non-steroidal anti-inflammatory 
drugs (NSAIDs) or glucocorticoids; 
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3.1.14. Not involved in regular organized physical activity for at least 1 year prior to 
enrollment, meaning that you exercise less than 3 times per week and that you do not 
engage in activities of moderate or vigorous intensity. 
3.1.15. Clearance from your primary physician, if you are age 65 years or older. 
 
Are there any reasons you should not be in this study? 
You should not be in this study if you have any type of disease that affects your heart, lungs, 
bones, or muscles which would make it very difficult for you to exercise. You should not be 
in this study if you have uncontrolled diabetes or thyroid disease.  You should not be in this 
study if you have had a fever, body aches, and/or swollen glands within the past 6 weeks or if 
you have a chronic infectious disease such as hepatitis or AIDS.  You should not be in this 
study if you have abnormally low values for certain blood markers, including potassium, 
magnesium, white blood cells, hematocrit, and platelets.  Also, you should not be in this 
study if you are currently using an anti-inflammatory medication such as non-steroidal anti-
inflammatory drugs (NSAIDs) or glucocorticoids, or you have any other mental or physical 
impairment that would prevent you from being able to exercise. 
 
How many people will take part in this study? 
If you decide to be in this study, you will be one of approximately 40 people in this research 
study. 
 
How long will your part in this study last?  
You will be asked to come to the laboratory for 3 separate visits.  Laboratory Visit 1 will last 
approximately 2 hours, Laboratory Visit 2 will last approximately 3 hours, and Laboratory 
Visit 3 will last approximately 30 minutes.  The overall length of time that you will 
participate in the study will be approximately 1-2 weeks, but may be shorter. 
 
As this study involves drawing blood, some of your blood samples may be frozen and stored 
indefinitely for future analyses.  You will be given a separate consent form describing 
storage of the blood samples. 
 
What will happen if you take part in the study? 
Participation in this study will require you to report to the laboratory for 3 separate visits.  All 
Laboratory Visits will take place in the Integrative Exercise Oncology Research Laboratory 
(IEORL), which is located in Fetzer Hall, in the Department of Exercise and Sport Science at 
UNC-Chapel Hill.  All study procedures are a requirement of participation in the study. 
 
Laboratory Visit 1: Orientation / Familiarization to the Study and 1-RM Assessment 
(Resistance Exercise Group Only) 
The purpose of Laboratory Visit 1 is to provide you with an overview of the study, give you 
an opportunity to ask questions about your participation, sign this informed consent, gather 
some demographic information about you, and to assess your muscular strength.  The 
specific procedures that will be performed are listed below: 
 
7. Sign informed consent documents 
8. Fill out a medical history questionnaire  
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9. Undergo a brief medical and physical screening, including a resting 
electrocardiogram (ECG) to measure heart function 
10. Undergo body composition analysis to assess percent body fat using a DEXA 
11. Familiarization with equipment used during exercise testing 
12. Undergo an exercise test to assess muscular strength 
 
The purposes of items 2, 3, and 4, are to determine if it is safe for you to participate in 
exercise and to gain some demographic information about you, including your age, height, 
weight, percent body fat, race, physical activity participation over the past year, and type of 
cancer treatments you have received and are currently receiving. The machine that will be 
used to measure your percent body fat in item 4 is called a DEXA.  DEXA stands for Dual 
Energy X-ray Absorptiometry.  The DEXA uses two x-ray beams to measure differences in 
the composition of different tissues in your body, such as bones, soft tissue, and fat.  The 
scan is performed while you rest on your back, and takes approximately 6 minutes.   
 
The purpose of item 6 is to perform an exercise assessment that will allow the researchers to 
determine your muscular strength, or the greatest amount of weight that certain muscle 
groups can lift one time.  This exercise assessment will involve performing 4 different 
exercises. They are: leg press, lateral pull down, leg extension, and seated row. The exercise 
assessment will involve a series of one-repetition trials with increasing workloads until you 
decide that the given weight is the most that you can lift with proper form. This will be done 
for each of the 4 exercises. The duration of the exercise assessment will likely last no more 
than 30 minutes. 
 
Laboratory Visit 2: Acute Resistance Exercise Session (Resistance Exercise Group Only) 
Laboratory Visit 2 will occur between 7-14 days of Laboratory Visit 1.  During this Visit, 
you will be performing 1 session of moderate-intensity resistance exercise on the same 4 
pieces of equipment used in Laboratory Visit 1 (leg press, lateral pull down, leg extension, 
and seated row).  This will be the exercise bout that will be used to elicit a response in your 
immune cells, inflammatory markers, and stress hormones.  The specific procedures that will 
be performed are listed below: 
 
6. Fill out a psychological stress questionnaire 
7. Pre-exercise blood sample 
8. Moderate-intensity resistance exercise session 
9. Post-exercise blood sample (immediately post-exercise) 
10. Post-exercise blood sample (2 hours post-exercise) 
 
The purpose of item 1 is to determine if you are feeling any emotional or psychological stress 
on the day of testing.  This is important information as the levels of stress hormones in your 
blood may be influenced by emotional or psychological stress. 
 
During item 3, you will be performing an approximately 30-minute bout of moderate-
intensity resistance exercise on the leg press, lateral pull down, leg extension, and seated row.  
A moderate intensity level of exercise will make you feel like your muscles are working, but 
you are able to carry on a conversation.  You will alternate between each of the four 
65 
 
resistance exercises, performing 10 repetitions of each followed by 1.5 minutes of rest before 
continuing on to the next exercise. You will move from the leg press to the lateral pull down 
to the leg extension to the seated row, with the same number of repetitions and amount of rest 
until you have completed each exercise three times.  
 
The 3 blood samples to be obtained during items 2, 4, and 5 will be performed by using a 
small catheter inserted into a vein in your arm.  This blood sampling procedure is very 
similar to a blood sampling procedure that is used in routine medical clinic settings.  
Approximately 1 tablespoon of blood will be collected for each item.  Some of this blood 
will be used during the course of this study to measure the number of NK cells in your blood, 
the activity of the NK cells (i.e., how well they destroy other cells), and the levels of stress 
hormones and cytokines in your blood.   
 
Laboratory Visit 3:  24-hour Follow-up Session  
 
Laboratory Visit 3 will occur 24 hours after Laboratory Visit 2.  During this Visit, you will 
answer the same psychological stress questionnaire as you did in the previous laboratory 
visit.  You will also have 1 blood sample drawn, which will also be used to the number of 
NK cells in your blood, the activity of the NK cells (i.e., how well they destroy other cells), 
and the levels of stress hormones and cytokines in your blood.  The procedure for obtaining 
the blood sample is the same as described above, except that the blood will be drawn through 
a small needle instead of a catheter. 
 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. The benefits to you from 
being in this study may be the opportunity to have your various aspects of your health 
assessed during Laboratory Visit 1.  This would include looking at how well your heart is 
working by using the ECG and by listening to your heart with a stethoscope.  Additionally, 
you will have your muscular strength assessed, as well as your percent body fat.  This 
information may be useful if you are be thinking of beginning an exercise program, and you 
may elect to provide this information to an exercise specialist who could construct and 
supervise an individualized exercise program for you. 
 
What are the possible risks or discomforts involved with being in this study?  
The risk of physiological and psychological harm is very minimal and would not cost you 
physical or emotional loss.  However, any research study does carry with it some potential 
for risk or discomfort, listed below:  
 
5. During Laboratory Visit 1, you will be performing an exercise test to determine your 
muscular strength.  The test will start with an easy warm-up and movement rehearsal 
for your muscles. As the one repetition maximum trials begin, you will find that the 
assessment will become more difficult.  It is possible that increased stress will be 
placed on your musculoskeletal system.  To ensure your safety, your heart rate and 
your lifting technique will be monitored continuously throughout the various trials to 
verify that there are no movement compensations. Your heart rate will continue to be 
monitored for several minutes after the conclusion of the one repetition maximum 
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assessments. At the conclusion of the test, you will be allowed to cool down, stretch, 
and drink water at liberty.   
 
6. During Laboratory Visit 1, you will be exposed to radiation during the DEXA scan.  
However, the scan itself is very safe, and the amount of x-ray radiation that you will 
receive during the scan is 0.8 mrems, which is extremely small.  To put this in 
perspective, this amount of radiation is about the same amount of radiation that you 
would receive from natural background sources in one day. 
 
7. During Laboratory Visits 1 and 2, it is possible that you could experience slight 
muscle or joint soreness after the exercise.  However, this soreness would not be any 
worse than after doing any other type of exercise.  To minimize the amount of 
soreness you might feel, you will be allowed to stretch before and after exercise, and 
you will be allowed to do a light warm-up and cool-down before and after exercise. 
 
8. During Laboratory Visits 2 and 3, it is possible that you could experience some mild 
bruising or discomfort while having your blood drawn.  This discomfort would not be 
any more significant than having your blood drawn at the doctor’s office.  The blood 
sampling procedures will be performed by research team members who have drawn 
blood many times before, and proper bandaging will be performed to minimize 
bleeding. 
 
In addition, there may be uncommon or previously unknown risks that might occur.  You 
should report any problems to the researchers. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might 
affect your willingness to continue your participation.   
 
How will your privacy be protected?   
You will not be identified in any report or publication about this study. Although every effort 
will be made to keep research records private, there may be times when federal or state law 
requires the disclosure of such records, including personal information.  This is very unlikely, 
but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to 
protect the privacy of personal information.  In some cases, your information in this research 
study could be reviewed by representatives of the University, research sponsors, or 
government agencies (for example, the FDA) for purposes such as quality control or safety.    
 
All data obtained from you during this study will be coded using a research ID number, and 
only the members of the research team will have access to these codes.  Study databases and 
logs will not have any information that will allow for subjects to be identified by anyone 
other than a research team member.   
 
A copy of this consent form will go in to your medical record.  This will allow the doctors 
caring for you to know what study tests you may be receiving as a part of the study and know 
how to take care of you if you have other health problems or needs during the study. 
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What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  This may include 
the risk of personal injury. In spite of all safety measures, you might develop a reaction or 
injury from being in this study. If such problems occur, the researchers will help you get 
medical care, but any costs for the medical care will be billed to you and/or your insurance 
company. The University of North Carolina at Chapel Hill has not set aside funds to pay you 
for any such reactions or injuries, or for the related medical care. However, by signing this 
form, you do not give up any of your legal rights. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have 
the right to stop your participation at any time. This could be because you have had an 
unexpected reaction, you become ill, you use a medication that may affect the outcome of the 
study variables being measured, you are not able to complete the exercise testing sessions, 
you refuse to have your blood drawn, you miss a Laboratory Visit, or because the entire 
study has been stopped.  If you decide to withdraw from the study, all data collected from 
you will be destroyed and will not be used in any data analyses that may result from this 
study. 
 
Will you receive anything for being in this study? 
You will be provided with a written report of your fitness level and percent body fat, both of 
which will be measured during Laboratory Visit 1.   
 
Will it cost you anything to be in this study? 
It will not cost you anything to participate in this study. 
 
What if you are a UNC student? 
You may choose not to be in the study or to stop being in the study before it is over at any 
time.  This will not affect your class standing or grades at UNC-Chapel Hill.  You will not be 
offered or receive any special consideration if you take part in this research. 
 
What if you are a UNC employee? 
Taking part in this research is not a part of your University duties, and refusing will not affect 
your job.  You will not be offered or receive any special job-related consideration if you take 
part in this research. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, complaints, concerns, or if a research-related injury occurs, 
you should contact the researchers listed on the first page of this form.  
 
What if you have questions about your rights as a research subject? 
All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare.  If you have questions or concerns about your rights as a research subject, 
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or if you would like to obtain information or offer input, you may contact the Institutional 
Review Board at 919-966-3113 or by email to IRB_subjects@unc.edu. 
 
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
Title of Study: The Impact of Acute Aerobic and Resistance Exercise on Natural Killer Cell, 
Catecholamine, and Cortisol Responses in Breast Cancer Survivors 
 
Principal Investigator: Claudio L. Battaglini, PhD 
 
Subject’s Agreement:  
 
I have read the information provided above.  I have asked all the questions I have at this time.  
I voluntarily agree to participate in this research study. 
 
_________________________________________________ __________________ 
Signature of Research Subject  Date 
 
_________________________________________________ 
Printed Name of Research Subject 
 
_________________________________________________ __________________ 
Signature of Research Team Member Obtaining Consent  Date 
 
_________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
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Appendix C 
 
MEDICAL HISTORY QUESTIONNAIRE 
Department of Exercise and Sport Science 
Medical History 
 
Subject: __________________________ ID: ___________  Telephone:______________ 
 
Address:________________________________________________________________ 
 
Occupation:___________________________________  Age:______________________ 
 
Race:________________________________________ 
 
          YES NO 
Patient History 
1. How would you describe your general health at present? 
Excellent______ Good_______ Fair______ Poor______ 
2.   Do you have any health problems at the present time?   _____ _____ 
3.  If yes, please describe:         
             
4.  Have you ever been told you have heart trouble?    _____ _____ 
5.  If yes, please describe:         
             
6.  Do you ever get pain in your chest?     _____ _____ 
7.  Do you ever feel light-headed or have you ever fainted?   _____ _____ 
8.  If yes, please describe:         
             
9.  Have you ever been told that your blood pressure has been elevated? _____ _____ 
10.  If yes, please describe:         
             
11.  Have you ever had difficulty breathing either at rest or with exertion? _____ _____ 
12.  If yes, please describe:         
             
13.  Are you now, or have you been in the past 5 years, under a doctor’s care for any reason?
          _____ _____ 
14.  If yes for what reason?         
           
 _____________________________________________________________________
_____________________ 
15.  Have you been in the hospital in the past 5 years?   _____ _____ 
16.  If yes, for what reason?         
             
17.  Have you ever experienced an epileptic seizure or been informed that you have epilepsy?
          _____ _____ 
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18.  Have you ever been treated for infectious mononucleosis, hepatitis, pneumonia, or 
another infectious disease during the past year?    _____ _____ 
19.  If yes, name the disease:          
20.  Have you ever been treated for or told you might have diabetes? _____ _____  
21.  Have you ever been treated for or told you might or low blood sugar? _____ _____ 
22.  Do you have any known allergies to drugs?    _____ _____ 
23.  If so, what?          
             
24.  Have you ever been “knocked-out” or experienced a concussion? _____ _____ 
25.  If yes, have you been “knocked-out” more than once?   _____ _____ 
26.  Have you ever experienced heat stroke or heat exhaustion?  _____ _____ 
27.  If yes, when?          
             
28.  Have you ever had any additional illnesses or operations? (Other than childhood 
diseases)          
 _____ _____ 
29.  If yes, please indicate specific illness or operations:     
           
 _____________________________________________________________________
_____________________ 
30.  Are you now taking any pills or medications?    _____ _____ 
31.  If yes, please list:          
          
 _____________________________________________________________________
__________________ 
32.  Have you had any recent (within 1 year) difficulties with your: 
 a.  Feet        _____ _____ 
 b.  Legs        _____ _____ 
 c.  Back        _____ _____ 
 
Family History 
33.  Has anyone in your family (grandparent, father, mother, and/or sibling) experienced any 
of the following? 
 a.  Sudden death       _____ _____ 
 b.  Cardiac disease       _____ _____ 
 c.  Marfan’s syndrome      _____ _____ 
 
Mental History 
34.  Have you ever experienced depression?     _____ _____ 
35.  If yes, did you seek the advice of a doctor?    _____ _____ 
36.  Have you ever been told you have or has a doctor diagnosed you with panic disorder, 
obsessive-compulsive disorder, clinical depression, bipolar disorder, or any other 
psychological disease?       _____ _____ 
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37.  If yes, please list condition and if you are currently taking any medication. 
Condition      Medication 
            
            
           
 __________________ 
 
Bone and Joint History 
34.  Have you ever been treated for Osgood-Schlatter’s disease?  _____ _____ 
35.  Have you ever had any injury to your neck involving nerves or  
vertebrae?         _____ _____ 
36.  Have you ever had a shoulder dislocation, separation, or other injury of the shoulder that 
incapacitated you for a week or longer?     _____ _____ 
37.  Have you ever been advised to or have you had surgery to correct a shoulder condition?
           _____
 _____ 
38.  Have you ever experienced any injury to your arms, elbows, or wrists?_____ _____ 
39.  If yes, indicate location and type of injury:      
             
40.  Do you experience pain in your back?     _____ _____ 
41.  Have you ever had an injury to your back?    _____ _____ 
42.  If yes, did you seek the advice of a doctor?    _____ _____ 
43.  Have you ever been told that you injured the ligaments or cartilage of either knee joint?
          _____ _____ 
44.  Do you think you have a trick knee?     _____ _____ 
45.  Do you have a pin, screw, or plate somewhere in your body as the result of bone or joint 
surgery that presently limits your physical capacity?    _____ ____ 
46.  If yes, indicate where:         
           
 ____________ 
47.  Have you ever had a bone graft or spinal fusion?   _____ _____ 
 
Activity History 
48.  During your early childhood (to age 12) would you say you were: 
 Very active ____ Quite active____ Moderately active____ Seldom active____ 
49.  During your adolescent years (age 13-18) would you say you were: 
 Very active ____ Quite active____ Moderately active____ Seldom active____ 
50.  Did you participate in: 
a. Intramural school sports?      _____ _____ 
b. Community sponsored sports?     _____ _____ 
c. Varsity school sports?      _____ _____ 
d. Active family recreation?      _____ _____ 
51.  Since leaving high school, how active have you been? 
 Very active ____ Quite active____  Active____  Inactive____ 
52.  Do you participate in any vigorous activity at present?   _____ _____ 
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53.  If yes, please list: 
Activity  Frequency   Duration  Intensity 
            
            
            
           
 ________________________ 
54.  How would you describe your present state of fitness? 
Excellent_____ Good_____ Fair_____ Poor_____ 
55.  Please list the type(s) of work you have been doing for the previous ten years: 
Year  Work    Indoor/Outdoor Location (city/state) 
            
           
 ____________ 
 
 
Menstrual Cycle History 
56.  Have you been post-menopausal for the past year, in that you have not experienced a 
menstrual period for at least 1 year?      _____ _____  
 
Emergency Contact Information  
57.  Whom shall we notify in case of emergency? 
 Name:            
 Phone: (Home)     (Work)     
 Address:           
58.  Name and address of personal physician:      
            
             
 
FOR SUBJECTS IN THE BREAST CANCER SURVIVOR GROUP ONLY 
59.  Please indicate which type(s) of treatment you received/are receiving for your cancer 
Surgery____ Chemotherapy____   Radiation Therapy____  Hormonal Therapy____ 
Trastuzumab_____ 
 
60.  How long ago did you finish receiving surgery, chemotherapy, and/or radiation therapy? 
__________________________________________________________________________ 
 
61.  If you received surgery, which type did you receive? 
Mastectomy ____  Lumpectomy____ 
 
62.  If you received chemotherapy, please list the names of the drugs that were included in 
your treatment. 
___________________________________________________________________________
___________________________________________________________________________ 
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63.  If you are receiving hormonal therapy, please list the names of the medications that you 
are taking and how long you have been taking them. 
___________________________________________________________________________
___________________________________________________________________________ 
 
64.  If you are receiving trastuzumab, please list how long you have been taking this 
medication. 
___________________________________________________________________________ 
 
65.  Please list any other medication(s) that you have taken/are currently taking that is/are 
directly related to your cancer treatment. 
___________________________________________________________________________ 
___________________________________________________________________________ 
 
 
 
All of the above questions have been answered completely and truthfully to the best of my 
knowledge. 
 
Signature:        Date:     
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Appendix D 
 
University of North Carolina-Chapel Hill 
HIPAA Authorization for Use and Disclosure of Health Information for Research 
Purposes 
 
IRB Study #11-1405 
 
Title of Study: The Impact of Resistance Exercise on Cellular Immune System Responses, 
Stress Hormones, and Cytokines in Breast Cancer Survivors 
 
Principal Investigator: Claudio L. Battaglini, PhD 
Mailing Address for UNC-Chapel Hill Department:  Department of Exercise & Sport 
Science, CB #8700 
________________________________________________________________________ 
  
This is a permission called a “HIPAA authorization.”  It is required by the “Health Insurance 
Portability and Accountability Act of 1996” (known as “HIPAA”) in order for us to get 
information from your medical records or health insurance records to use in this research 
study.   
________________________________________________________________________ 
 
1. If you sign this HIPAA authorization form, you are giving your permission for the 
following people or groups to give the researchers certain information about you (described 
below): 
 
Any health care providers or health care professionals or health plans that have provided 
health services, treatment, or payment for you such as physicians, clinics, hospitals, home 
health agencies, diagnostics centers, laboratories, treatment or surgical centers, including but 
not limited to the UNC Health Care System, health insurance plans, and government health 
agencies.  
 
2. If you sign this form, this is the health information about you that the people or groups 
listed in #1 may give to the researchers to use in this research study any information in your 
medical records that relates to your participation in this research.  These records might 
include information about your age, race, height, weight, menopausal status, physical activity 
participation over the past year, breast cancer stage at diagnosis, types of cancer therapies 
and drugs you have received, medications you may be taking, and presence of any other 
diseases that could preclude your ability to exercise, including cardiovascular disease, 
pulmonary disease, orthopedic disease, diabetes, thyroid disease, and chronic infectious 
disease including hepatitis or AIDS.  
 
3. The HIPAA protections that apply to your medical records will not apply to your 
information when it is in the research study records.  Your information in the research study 
records may also be shared with, used by or seen by collaborating researchers, the sponsor of 
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the research study, the sponsor’s representatives, and certain employees of the university or 
government agencies (like the FDA) if needed to oversee the research study.   
 
HIPAA rules do not usually apply to those people or groups.   If any of these people or 
groups reviews your research record, they may also need to review portions of your original 
medical record relevant to the situation.  The informed consent document describes the 
procedures in this research study that will be used to protect your personal information. You 
can also ask the researchers any questions about what they will do with your personal 
information and how they will protect your personal information in this research study.  
 
4. If this research study creates medical information about you that will go into your medical 
record, you may not be able to see the research study information in your medical record 
until the entire research study is over. 
 
5. If you want to participate in this research study, you must sign this HIPAA authorization 
form to allow the people or groups listed in #1on this form to give access to the information 
about you that is listed in #2.  If you do not want to sign this HIPAA authorization form, you 
cannot participate in this research study. However, not signing the authorization form will 
not change your right to treatment, payment, enrollment or eligibility for medical services 
outside of this research study.  
 
6.  This HIPAA authorization will not stop unless you stop it in writing.  
 
7. You have the right to stop this HIPAA authorization at any time.   You must do that in 
writing.  You may give your written stop of this HIPAA authorization directly to Principal 
Investigator or researcher or you may mail it to the department mailing address listed at the 
top of this form, or you may give it to one of the researchers in this study and tell the 
researcher to send it to any person or group the researcher has given a copy of this HIPAA 
authorization.  Stopping this HIPAA authorization will not stop information sharing that has 
already happened.   
 
8. You will be given a copy of this signed HIPAA authorization. 
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___________________________________   _________ 
Signature of Research Subject    Date 
 
___________________________________ 
Print Name of Research Subject 
For Personal Representative of the Research Participant (if applicable) 
Print Name of Personal Representative: ___________________________ 
Please explain your authority to act on behalf of this Research Subject: 
_________________________________________________________ 
I am giving this permission by signing this HIPAA Authorization on behalf of the Research 
Participant. 
 
___________________________________   _________ 
Signature of Personal Representative   Date 
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Appendix E 
 
University of North Carolina at Chapel Hill 
Consent for Storing Biological Specimens With Identifying Information 
_______________________________________________________________________ 
 
IRB Study # 11-1405 
Consent Form Version Date:  November 2, 2012 
 
Title of Study:  The Impact of Resistance Exercise on Cellular Immune System Responses, 
Stress Hormones, and Cytokines in Breast Cancer Survivors 
 
Principal Investigator:  Claudio L. Battaglini, PhD 
Principal Co-Investigator: Anthony C. Hackney, PhD, DSc 
UNC-Chapel Hill Department:  Exercise & Sport Science 
UNC-Chapel Hill Phone number:  843-6045 
Email Address:  claudio@email.unc.edu 
Co-Investigators:  Lisa A. Carey; Hyman B. Muss, MD; Eric D. Ryan, PhD; Elizabeth 
Evans, MA; Rachel Graff BA; Jacob Allen, BA; Dustin Buttars, BS; Robert Mills, BA; Sarah 
Fultz, BS; and Mary Woessner, B.A. 
 
Funding Source and/or Sponsor: Lineberger Comprehensive Cancer Center 
 
Study Contact telephone number:  (516) 633-5235 or (919) 621-1322 
Study Contact email:  rgraff1@email.unc.edu or jmallen@email.unc.edu 
________________________________________________________________________ 
 
What are some general things you should know about research? 
Research is designed to gain scientific information that may help other people in the future.  
You may not receive any direct benefit from participating. There also may be risks. 
 
You may refuse to take part in research.  If you are a patient with an illness, you do not have 
to be in research in order to receive treatment.  
 
Details are discussed below.  It is important that you understand this information so that you 
can make an informed choice.  You will be given a copy of this consent form.  You should 
ask the researchers named above, or staff members who may assist them, any questions you 
have about this study at any time. 
 
What is the purpose of this specimen repository or “biobank?” 
Research with blood, tissue or body fluids (specimens) can help researchers understand how 
the human body works.  Research can also answer other questions by using specimens.  
Researchers may develop new tests to find diseases, or new ways to treat diseases.  In the 
future, research may help to develop new products, such as drugs.  Specimens are commonly 
used for genetic research.  Sometimes researchers collect and store many specimens together 
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and use them for different kinds of research, or share them with other scientists; this is called 
a specimen repository or “biobank.” 
 
The purpose of this particular repository or biobank is to allow researchers to conduct future 
analysis of blood samples that will be obtained during the course of this study.  For this 
particular study, blood samples will be collected in order to measure immune and 
inflammatory markers in the blood in response to one session of moderate-intensity 
resistance exercise.  Additionally, levels of the stress hormone cortisol will be measured.  
Future analyses that may be performed on these blood samples may include measuring the 
levels of other hormones as well as the levels of other components of the immune system that 
may be affected by resistance exercise.   
 
How will the specimens be collected? 
Blood samples are collected as part of the main study.  We would like to store any samples 
remaining for future use. 
 
What will happen to the specimens? 
Once your blood samples are collected, they will be frozen and stored in a freezer located in 
the Applied Physiology Laboratory, Room 25 Fetzer Hall, in the Department of Exercise and 
Sport Science at UNC-Chapel Hill.  The freezer is kept within a self-contained section of the 
laboratory that is accessible only by a keypad combination on a closed door.  The only 
individuals with access to the freezer are faculty of the Applied Physiology Laboratory and 
their graduate students.  Blood samples will be kept in the freezer indefinitely until it is 
apparent that an insufficient amount exists needed to perform analysis.  The only other 
investigators besides those on the research team who would have access to your blood 
samples and accompanying data would be future graduate students of the Principal 
Investigator. 
 
What are the possible benefits to you? 
Benefits to you are unlikely. Studies that use specimens from this repository may provide 
additional information that will be helpful in understanding the effect of acute resistance 
exercise on hormone responses and immune system responses in breast cancer survivors and 
healthy women who have never been diagnosed with or received treatment for cancer.  
 
What are the possible risks or discomforts involved with the use of your specimens? 
The risk of physiological and psychological harm related to specimen collection is very 
minimal and would not cost you physical or emotional loss. However, any research study 
does carry with it some potential for risk or discomfort. Additionally, there is a risk of breach 
of confidentiality; however, your stored blood samples will be coded using a research ID 
number that will not be linked with any information that would personally identify you. 
 
Will there be any cost to you for storage of the specimens? 
There will be no cost to you for the storage and use of the specimens for research purposes. 
 
Will you receive anything for the use of your specimens? 
You will not receive anything for taking part in this research. 
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Who owns the specimens? 
Any blood, body fluids, or tissue specimens obtained for this purpose become the exclusive 
property of the University of North Carolina at Chapel Hill.  This organization may retain, 
preserve or dispose of these specimens and may use these specimens for research that may 
result in commercial applications.  There are no plans to compensate you for any future 
commercial use of these specimens. 
 
How will your privacy be protected? 
All data obtained from you during this study will be coded using a research ID number, and 
only the members of the research team will have access to these codes.  Study databases and 
logs will not have any information that will allow for subjects to be identified by anyone 
other than a research team member.   
 
Information from your medical records may be stored along with your specimens(s).  You 
will be asked to sign a separate form (“HIPAA authorization”) to allow researchers to review 
your medical records.   
 
You will not be identified in any report or publication about research using your specimens. 
Although every effort will be made to keep research records private, there may be times 
when federal or state law requires the disclosure of such records, including personal 
information.  This is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will 
take steps allowable by law to protect the privacy of personal information.  In some cases, 
your information in this research could be reviewed by representatives of the University, 
research sponsors, or government agencies for purposes such as quality control or safety. 
 
Will researchers seek approval from you to do future studies involving the specimens? 
By signing this consent form, you are giving your permission for researchers to use your 
specimens as described above.  Current and future research is overseen by a committee called 
the Institutional Review Board (IRB).  The role of the IRB is to protect the rights and welfare 
of research participants.  In some cases, the IRB may require that you be re-contacted and 
asked for your consent to use your specimens in a specific research study.  You have the 
right, at that future time, not to participate in any research study for which your consent is 
sought.  Refusal to participate will not affect your medical care or result in loss of benefits to 
which you are entitled. 
 
 
Will you receive results from research involving your specimens? 
Most research with your specimens is not expected to yield new information that would be 
meaningful to share with you personally.  There are no plans to re-contact you or other 
subjects with information about research results. 
 
Can you withdraw the specimens from the research repository? 
If you decide that you no longer wish for the specimens to be stored, you should contact the 
researchers on the front page of this form.  It is best to make your request in writing. 
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Any analysis in progress at the time of your request or already performed prior to your 
request being received by the researcher will continue to be used as part of the research 
study.  Once the researchers have been notified, your remaining specimens would be 
destroyed.  If you do not make such a request, the specimens may be stored forever.  The 
researchers may choose to destroy the specimens at any time. 
 
What will happen if you are injured by this research? 
NA 
 
What if you have questions about this research? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, you should contact the researchers listed on the first page of 
this form. 
 
What if you have questions about your rights as a research subject? 
All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare.  If you have questions or concerns about your rights as a research subject 
you may contact, anonymously if you wish, the Institutional Review Board at 919-966-3113 
or by e-mail to IRB_ subjects@unc.edu. 
________________________________________________________________________ 
IRB Study # 11-1405:  The Impact of Resistance Exercise on Cellular Immune System 
Responses, Stress Hormones, and Cytokines in Breast Cancer Survivors 
 
Subject’s Agreement: 
 
I have read the information provided above.  I have asked all the questions I have at this time.  
I voluntarily agree to participate.  I agree to my specimen(s) being stored with the identifying 
code(s). 
 
_________________________________________________  _________________ 
Signature of Research Subject       Date 
___________________________________________ 
Printed Name of Research Subject 
_________________________________________________ _________________ 
Signature of Research Team Member Obtaining Consent   Date 
__________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
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Appendix F 
 
Laboratory Visit Appointment Reminder 
 
Thank you for agreeing to participate in this study entitled “The Impact of Acute Aerobic and 
Resistance Exercise on Natural Killer Cell, Catecholamine, and Cortisol Responses in Breast 
Cancer Survivors.” Your time and participation is greatly appreciated! 
 
 
This is an appointment reminder for Laboratory Visit (circle one): 1 2 3 
 
 
Your next Laboratory Visit is scheduled for ________________     __at ________ _____. 
          Date       Time 
 
Your Laboratory Visit will take place in the Integrative Exercise Oncology Research 
Laboratory (IEORL), which is room 125 Fetzer Hall (corner of South Rd and Raleigh Rd). 
 
If you are driving into campus, here are the directions for arriving to Fetzer Hall and parking.  
These directions are written assuming you are coming from the direction of UNC Hospitals.  
1. Drive south on Columbia Street until you come to the intersection of South Rd. and 
Columbia. 
2. Turn right onto South Rd. 
3. Drive a short distance on South Rd. and turn right onto Stadium Drive.  The bell 
tower will be on your right. 
4. Drive a very short distance on Stadium Drive and take your first left.  The football 
stadium will be on your right, and there will be several crosswalk lines painted on the 
asphalt. 
5. You are now in the small visitor parking lot at the junction of Fetzer Hall, the outdoor 
pool, and the Stallings-Evans Sports Medicine Facility.  Park in any of the available 
visitor parking spaces. 
6. One of us (Rachel Graff or Jacob Allen) will meet you in the parking lot with your 
pink visitor parking pass.   
 
***Please follow these pre-assessment guidelines prior to reporting to your Laboratory 
Visit*** 
 
1. No eating for at least 2 hours prior to your appointment.  We do suggest that you eat a 
little something before you come to the lab, even if it is early in the morning. 
2. No exercise for at least 12 hours prior to your appointment  
3. Drink water throughout the day to keep yourself hydrated. 
4. No caffeine use for at last 12 hours prior to your appointment  
5. No alcohol use for at least 48 hours prior to your appointment  
 
What to bring to your Laboratory Visit: 
1. Clothing (including shoes) that are comfortable for exercise. 
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2. Water bottle. 
3. Filled-out copies of the informed consents and medical history form. 
 
If you have any questions at any time, please do not hesitate to contact Rachel Graff or Jacob 
Allen at (516) 633-5235 or (919) 621-1322 or rgraff1@email.unc.edu or 
jmallen@email.unc.edu. 
 
 
Again, thank you for your participation! 
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Appendix H 
 
Data Collection Form: Visit 1 
 
Subject: 
 
ID:__________________________ 
 
Height:___________________ (cm) 
 
Weight:___________________(kg) 
 
Resting HR_________ (BPM)     Heart rate reserve (50%)____________________(HRR)   
 
Resting BP____________ (mmHg) 
 
Body fat (%): ____________ 
 
 
One Repetition Max: 
 
Leg Press:_______________ (lbs)    Machine Settings:_________________ 
 
Lateral Pull Down:________________ (lbs)  Machine Settings:_________________ 
 
Leg Extension :________________ (lbs)  Machine Settings:_________________ 
 
Seated Row:_______________ (lbs)   Machine Settings:_________________ 
 
 
Post-Exercise Measures: 
 
Final HR____________ (BPM)    
 
Final BP________________ (mmHg) 
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